This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Complications peculiar to reattachment and amputation
ST19_COMPLICATIO_PECUL_REATTACHM_AMPUT
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
262 |
4. Check minimum number of eventsNone |
262 |
5. Include endpointsNone |
262 |
6. Filter based on genotype QC (FinnGen only) |
255 |
Control definitions (FinnGen only)
- Control exclude
- ST19_COMPLICATIO_SURGI_MEDICAL_CARE_NOT_ELSEW_CLASSIFIED
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- T8
- Name in latin
- Complicationes specificae recompingendi et amputationis
Similar endpoints
↥List of similar endpoints to
Complications peculiar to reattachment and amputation
based on the number of shared cases.
Similar with more cases:
- Complications of surgical and medical care, not elsewhere classified
- Injury, poisoning and certain other consequences of external causes
- Any operation in hilmo
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 255 | 98 | 157 |
| Unadjusted period prevalence (%) | 0.06 | 0.03 | 0.07 |
| Median age at first event (years) | 65.14 | 63.03 | 66.45 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 262
- Matched controls
- 2620
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
42.1
175.1
118
50
T87.4
ICD-10 Finland
Infection of amputation stump
3303.2
171.8
147
*
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
86.3
160.8
87
15
QDB05
NOMESCO Finland
Revision of wound of skin of lower limb
60.5
160.6
94
24
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
100.8
157.6
83
12
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
22.8
151.1
152
150
NHQ40
NOMESCO Finland
Amputation of toe
72.3
150.4
84
17
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
30.5
125.3
91
45
S97
ICPC
Chronic ulcer skin
18.3
107.8
104
91
E11.5
ICD-10 Finland
Type 2 diabetes mellitus, with peripheral circulatory complications
31.6
91.6
63
26
NGQ20
NOMESCO Finland
Amputation of lower leg
190.7
80.2
80
6
T87.6
ICD-10 Finland
Other and unspecified complications of amputation stump
+∞
72.3
66
*
NFQ20
NOMESCO Finland
Amputation of femur
316.5
72.2
70
*
PD4BC
NOMESCO Finland
Extensive arterigography of lower extremity with X-ray
38.3
66.2
42
13
SPAT1148
SPAT
Treatment of chronic ulcer or burn
9.0
65.8
110
195
PD4AC
NOMESCO Finland
Arterigography of lower extremity with X-ray
30.0
65.4
45
18
J01FF01
ATC
clindamycin; systemic
8.0
63.9
163
447
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
11.1
61.0
76
93
ZZA00
NOMESCO Finland
Split skin graft
21.5
60.8
48
27
L98.4
ICD-10 Finland
Chronic ulcer of skin, not elsewhere classified
24.8
57.0
42
20
WX212
NOMESCO Finland
Femoral plexus blockade
24.8
57.0
42
20
NHQ30
NOMESCO Finland
Amputation of foot, transmetatarsal
225.5
54.2
54
*
ZXD05
NOMESCO Finland
Urgent procedure
6.8
53.8
160
491
L89
ICD-10 Finland
Decubitus ulcer and pressure area
20.4
53.5
43
25
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
9.8
52.4
71
96
QDG20
NOMESCO Finland
Operation for chronic ulcer or fistula of skin of lower limb
123.0
47.7
50
5
A46
ICD-10 Finland
Erysipelas
6.4
46.6
108
258
X59
ICD-10 Finland
Exposure to unspecified factor
6.3
45.9
108
261
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
9.1
45.4
64
90
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
16.5
40.7
36
25
TQW11
NOMESCO Finland
Vacuum treatment of wound
87.5
40.3
44
6
A10AE04
ATC
insulin glargine; parenteral
6.6
40.1
80
163
L03.1
ICD-10 Finland
Cellulitis of other parts of limb
13.7
39.4
39
33
C03CA01
ATC
furosemide; systemic
5.1
37.9
165
651
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.1
36.2
78
170
A41.9
ICD-10 Finland
Sepsis, unspecified
10.5
36.1
43
48
SPAT1144
SPAT
Treatment of reopened or infected surgical wound
8.3
35.3
52
76
A10AB05
ATC
insulin aspart; parenteral
6.5
34.7
67
131
PF1AT
NOMESCO Finland
Intravascular dilatation of arteries of knee, lower leg and ankle (PTA)
65.1
34.3
39
7
N03AX16
ATC
[U] pregabalin
4.8
33.2
111
349
A10AC01
ATC
insulin (human); parenteral
6.2
33.1
67
137
Y88.3
ICD-10 Finland
Sequelae of surgical and medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
69.2
32.0
36
6
NGQ48
NOMESCO Finland
Revision of exarticulation or amputation stump of knee or lower leg
352.8
31.5
31
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.6
31.5
109
350
WX213
NOMESCO Finland
Lower leg blockade
77.7
30.7
34
5
SPAT1255
SPAT
Intravenous administration of medicine
7.2
30.1
50
83
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.7
29.8
95
285
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
5.4
29.5
71
169
A10AB04
ATC
insulin lispro; parenteral
9.4
29.0
37
45
L02.4
ICD-10 Finland
Cutaneous abscess, furuncle and carbuncle of limb
9.2
28.5
37
46
J01MA02
ATC
ciprofloxacin; systemic
4.1
28.4
158
704
ZXA05
NOMESCO Finland
Left side
4.2
27.8
111
391
Y83.9
ICD-10 Finland
Surgical procedure, unspecified as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
+∞
26.5
25
*
ZXA00
NOMESCO Finland
Right side
4.0
26.5
116
434
J01CF05
ATC
flucloxacillin; systemic
6.4
25.7
47
86
N02AX02
ATC
tramadol; systemic, rectal
3.9
25.5
166
805
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
100.0
25.2
27
*
M86.9
ICD-10 Finland
Osteomyelitis, unspecified
48.2
25.2
30
7
I70.9
ICD-10 Finland
Generalized and unspecified atherosclerosis
25.0
25.1
35
16
T87.3
ICD-10 Finland
Neuroma of amputation stump
+∞
24.3
23
*
Z89.5
ICD-10 Finland
Acquired absence of leg at or below knee
263.1
24.1
24
*
NG4AA
NOMESCO Finland
Lower leg X-ray examination
9.1
24.0
31
38
WX408
NOMESCO Finland
General anesthesy, balanced
3.9
23.9
99
352
N03AX12
ATC
[U] gabapentin; oral
4.2
23.9
81
250
L28
ICPC
Limited function/disability (L)
4.0
23.7
91
307
A10AB01
ATC
insulin (human); parenteral
7.8
23.5
35
51
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
4.5
23.5
69
191
I50.9
ICD-10 Finland
Heart failure, unspecified
4.0
23.5
91
309
PF1BT
NOMESCO Finland
Extensive PTA of arteries of knee, lower leg and ankle
71.8
23.3
26
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.9
23.2
39
65
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.2
22.9
76
230
N02AA05
ATC
oxycodone; systemic
3.9
22.8
94
332
A10AE05
ATC
insulin detemir; parenteral
6.2
22.5
42
78
NFQ48
NOMESCO Finland
Revision of exarticulation or amputation stump of hip or femur
+∞
22.2
21
*
PD4CG
NOMESCO Finland
Extensive MRI examination of abdominal aortta and vasculature of lower extremities with high intensity magnet
29.4
21.9
29
11
J01MA12
ATC
levofloxacin; systemic
3.8
21.7
87
300
SPAT1229
SPAT
Assessment of need for aid
5.6
21.5
45
93
Y83.5
ICD-10 Finland
Amputation of limb(s) as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
+∞
21.1
20
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
20.5
21.0
31
17
SPAT1149
SPAT
Suture or treatment of traumatic wound
4.3
20.7
65
188
X58
ICD-10 Finland
Exposure to other specified factors
4.3
20.4
64
185
E11.6
ICD-10 Finland
Type 2 diabetes mellitus, with other specified complications
8.4
20.4
28
37
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
7.2
20.1
32
50
WX320
NOMESCO Finland
Spinalanesthesy
3.5
20.1
98
382
WX872
NOMESCO Finland
Intensive care
6.4
20.1
36
64
QDA10
NOMESCO Finland
Incision of skin of lower limb
79.5
20.0
22
*
B01AC04
ATC
clopidogrel; oral
3.6
19.8
86
311
A10AA02, ,
ATC
6.6
19.7
34
58
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
5.4
19.5
42
89
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.8
19.3
76
257
E10.5
ICD-10 Finland
Type 1 diabetes mellitus, With peripheral circulatory complications
59.7
19.2
22
*
T81.3
ICD-10 Finland
Disruption of operation wound, not elsewhere classified
+∞
19.0
18
*
103
Kela drug reimbursment
Diabetes, insulin-treated
3.2
18.8
121
554
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
4.3
18.4
56
157
A28
ICPC
Limited function/disability NOS
3.4
18.4
88
337
TPH07
NOMESCO Finland
Cathetrisation of artery
4.4
18.4
53
143
PE1AT
NOMESCO Finland
Femoral artery PTA
29.2
18.2
24
9
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
5.5
17.9
38
79
CKC12
NOMESCO Finland
Photocoagulation of retina
6.1
17.9
33
60
Y83.8
ICD-10 Finland
Other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
+∞
17.9
17
*
S76
ICPC
Skin infection other
5.8
17.8
35
68
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
15.4
17.8
29
21
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
5.6
17.7
36
72
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
45.5
17.6
21
5
SPAT1262
SPAT
Handing over of treatment supplies
3.5
17.3
78
286
L03.9
ICD-10 Finland
Cellulitis, unspecified
23.9
17.2
24
11
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
6.7
16.8
28
46
I25.1
ICD-10 Finland
Atherosclerotic heart disease
3.0
16.7
108
490
H43.1
ICD-10 Finland
Vitreous haemorrhage
7.7
16.4
24
34
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
6.7
16.3
27
44
E11.00
ICD-10 Finland
Non-insulin dependent diabetes diabetic hypoglycaemic coma
6.3
16.2
29
51
N18.8
ICD-10 Finland
Other chronic renal failure
12.9
16.0
28
24
M86.6
ICD-10 Finland
Other chronic osteomyelitis
64.1
16.0
18
*
I50.0
ICD-10 Finland
Congestive heart failure
4.0
15.9
51
148
E11.3
ICD-10 Finland
Type 2 diabetes mellitus, with ophthalmic complications
6.3
15.8
28
49
NDQ20
NOMESCO Finland
Amputation of finger
90.6
15.8
17
*
A11CC03
ATC
alfacalcidol; systemic
12.4
15.7
28
25
PD4DE
NOMESCO Finland
Lower extremity artery ultrasound examination with Doppler method
14.3
15.6
26
20
H36.03
ICD-10 Finland
Proliferative diabetic retinopathy
30.8
15.4
20
7
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.9
15.4
106
494
ZXE20
NOMESCO Finland
More than three and less than five hours
3.7
15.2
57
184
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
12.4
15.2
27
24
QXB99
NOMESCO Finland
Other procedure to treat skin wound, unspecified location
17.9
15.1
23
14
ZXE10
NOMESCO Finland
More than one and less than three hours
2.8
14.8
117
584
I79.2*E11.5
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic peripheral angiopathy
85.0
14.7
16
*
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
13.7
14.7
25
20
T87.5
ICD-10 Finland
Necrosis of amputation stump
+∞
14.7
14
*
WX210
NOMESCO Finland
Plexus blockade of nervus ichiadicus
+∞
14.7
14
*
S18
ICPC
Laceration/cut
2.8
14.6
151
864
ZXE00
NOMESCO Finland
One hour or less
2.8
14.5
126
659
E10.4
ICD-10 Finland
Type 1 diabetes mellitus, With neurological complications
45.2
14.3
17
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
14.0
110
544
Z49.1
ICD-10 Finland
Extracorporeal dialysis
25.5
14.0
19
8
PE1BT
NOMESCO Finland
Femoral artery extensive PTA
25.5
14.0
19
8
A10AA01, ,
ATC
6.7
14.0
23
37
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
5.2
13.9
30
63
WX306
NOMESCO Finland
Lumbar epidural anesthesy
6.3
13.8
24
41
ZXE30
NOMESCO Finland
More than five and less than seven hours
6.5
13.6
23
38
E87.5
ICD-10 Finland
Hyperkalaemia
12.5
13.6
24
21
TK800
NOMESCO Finland
Hemodialysis
12.5
13.6
24
21
E10.2
ICD-10 Finland
Type 1 diabetes mellitus, With renal complications
22.6
13.5
19
9
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
22.6
13.5
19
9
T89
ICPC
Diabetes insulin dependent
5.4
13.4
28
57
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
5.2
13.4
29
61
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.5
13.4
53
177
S91.3
ICD-10 Finland
Open wound of other parts of foot
11.9
13.3
24
22
H3603, E103,
ICD-10 Finland
42.4
13.3
16
*
S81.8
ICD-10 Finland
Open wound of other parts of lower leg
6.4
13.3
23
39
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.7
13.1
97
462
NGM10
NOMESCO Finland
Fasciotomy of of knee or lower leg
30.1
13.1
17
6
B01AA03
ATC
warfarin; systemic
2.9
13.0
82
360
T36
ICD-10 Finland
Poisoning by systemic antibiotics
6.4
12.8
22
37
PD4CC
NOMESCO Finland
Very extensive arterigography of lower extremity with X-ray
33.9
12.7
16
5
N17.9
ICD-10 Finland
Acute renal failure, unspecified
5.4
12.7
26
52
J01DB01
ATC
cefalexin; oral
3.9
12.6
231
1723
QDG99
NOMESCO Finland
Other operation for chronic ulcer or fistula of skin of lower limb
+∞
12.6
12
*
T87.2
ICD-10 Finland
Complications of other reattached body part
+∞
12.6
12
*
S88.1
ICD-10 Finland
Traumatic amputation at level between knee and ankle
+∞
12.6
12
*
T84.0
ICD-10 Finland
Mechanical complication of internal joint prosthesis
+∞
12.6
12
*
Y88
ICD-10 Finland
Sequelae with surgical and medical care as external cause
136.3
12.5
13
*
Y89.9
ICD-10 Finland
Sequelae of unspecified external cause
39.6
12.3
15
*
QDB10, ,
SPAT
9.4
12.3
25
29
AN1
HP
Coronary angiography
3.3
12.3
53
186
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
10.0
12.3
24
26
L29
ICPC
Musculoskeletal sympt/complt other
4.1
12.3
37
102
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.5
12.2
32
79
Y88.1
ICD-10 Finland
Sequelae of misadventures to patients during surgical and medical procedures
49.1
12.0
14
*
2500A
ICD-9 Finland
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE,TYYPPI II]
6.3
12.0
21
36
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
4.4
11.9
32
81
E10.3
ICD-10 Finland
Type 1 diabetes mellitus, With ophthalmic complications
9.3
11.8
24
28
S19
ICPC
Skin injury other
5.6
11.8
23
44
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
24.2
11.7
16
7
R02
ICD-10 Finland
Gangrene, not elsewhere classified
68.1
11.7
13
*
TQW40
NOMESCO Finland
Remowal of suture of skin
4.5
11.7
30
73
SPAT1104
SPAT
Monitoring of emergency patient
4.6
11.6
29
69
K29
ICPC
Cardiovascular sympt/complt other
5.8
11.6
22
41
Z89.6
ICD-10 Finland
Acquired absence of leg above knee
+∞
11.5
11
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.1
11.5
58
223
QD9S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in lower extremities, unspecified
125.3
11.5
12
*
L03.0
ICD-10 Finland
Cellulitis of finger and toe
3.8
11.5
38
112
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
36.8
11.4
14
*
AA1AD
NOMESCO Finland
CT of head and brain
2.5
11.3
99
506
PEH56
NOMESCO Finland
Bypass from femoral to popliteal artery above knee
21.2
11.3
16
8
N08.39
ICD-10 Finland
Glomerular disorders in diabetes mellitus microalbuminuria
26.4
11.3
15
6
H3603, E113,
ICD-10 Finland
14.8
11.1
18
13
H36.01
ICD-10 Finland
Diabetic maculopathy
14.8
11.1
18
13
TPH04
NOMESCO Finland
Cathetrisation of vein
2.7
11.1
77
352
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.9
11.1
62
253
B03XA02
ATC
darbepoetin alfa; parenteral
11.3
11.0
20
19
B01AB05
ATC
enoxaparin; parenteral
2.5
10.9
97
499
SPAT1151
SPAT
Treatment of major wounds
18.8
10.9
16
9
CKC15
NOMESCO Finland
Panretinal photocoagulation
22.6
10.8
15
7
H3601, E113,
ICD-10 Finland
9.8
10.7
21
23
L17
ICPC
Foot/toe symptom/complaint
2.5
10.7
97
502
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.9
10.7
59
238
QDB99
NOMESCO Finland
Other procedure for wound of skin of lower limb
62.6
10.7
12
*
Y69
ICD-10 Finland
Unspecified misadventure during surgical and medical care
62.6
10.7
12
*
L14
ICPC
Leg/thigh symptom/complaint
3.5
10.7
40
128
C07AB07
ATC
bisoprolol; oral
2.4
10.7
162
1053
PE1YT
NOMESCO Finland
Femoral or popliteal artery PTA with stent
15.0
10.6
17
12
I74.3
ICD-10 Finland
Embolism and thrombosis of arteries of lower extremities
15.0
10.6
17
12
WX702
NOMESCO Finland
Supraglottic ventilation device
4.6
10.6
26
61
I20.81
ICD-10 Finland
Other angina pectoris stenosed coronary artery
3.5
10.6
40
129
NHQ60
NOMESCO Finland
Revision of ampution or exarticulation of ankle or foot
114.4
10.5
11
*
G54.6
ICD-10 Finland
Phantom limb syndrome with pain
+∞
10.5
10
*
Z44.1
ICD-10 Finland
Fitting and adjustment of artificial leg (complete)(partial)
+∞
10.5
10
*
FN1BC
NOMESCO Finland
Extensive angiography of hear and/or coronary arteries
4.4
10.4
27
66
C03DA01
ATC
spironolactone; oral
3.0
10.4
51
193
T90
ICPC
Diabetes non-insulin dependent
2.5
10.3
89
449
SPAT1254
SPAT
Administration of medicine
2.9
10.3
54
212
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
3.3
10.2
43
148
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.4
10.2
107
589
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
4.9
10.2
23
50
NH3CG
NOMESCO Finland
Extensive MRI of foot
41.8
10.0
12
*
QWA00
NOMESCO Finland
Repair of wound dehiscence in surgery of skin
41.8
10.0
12
*
J01DA01
ATC
[U] cefalexin
2.4
10.0
177
1216
WX892
NOMESCO Finland
Monitored bed care
3.7
10.0
34
102
L84
ICD-10 Finland
Corns and callosities
5.2
10.0
21
43
E10.00
ICD-10 Finland
Insulin-dependent diabetes diabetic hypoglycemic coma
27.2
9.9
13
5
Z49.2
ICD-10 Finland
Other dialysis
27.2
9.9
13
5
137
Kela drug reimbursment
Uraemia requiring dialysis
27.2
9.9
13
5
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.3
9.9
148
945
A12AA04
ATC
calcium carbonate; oral
14.1
9.8
16
12
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
5.6
9.8
19
36
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.4
9.7
99
536
QDE35
NOMESCO Finland
Repair of skin defect in lower limb after surgery or injury
57.2
9.7
11
*
NDQ48
NOMESCO Finland
Revision or amputation or exarticulation of finger
57.2
9.7
11
*
WX214
NOMESCO Finland
Plexus blockade at the ankle
57.2
9.7
11
*
TNX92
NOMESCO Finland
Supporting bandage or orthosis of lower limb
9.7
9.7
19
21
D64.9
ICD-10 Finland
Anaemia, unspecified
3.0
9.7
48
182
PEF23
NOMESCO Finland
Thrombendarterectomy of femoral artery
15.8
9.6
15
10
I21.49
ICD-10 Finland
Acute subendocardial infarction unspecified coronary artery status
3.6
9.6
34
105
PD3YT
NOMESCO Finland
Pelvic artery PTA with stent
18.4
9.5
14
8
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
18.4
9.5
14
8
N18.5
ICD-10 Finland
Chronic kidney disease, stage 5
31.3
9.5
12
*
T81.8
ICD-10 Finland
Other complications of procedures, not elsewhere classified
103.6
9.5
10
*
K92
ICPC
Atherosclerosis/periph vascular dis
22.7
9.4
13
6
T84.5
ICD-10 Finland
Infection and inflammatory reaction due to internal joint prosthesis
+∞
9.4
9
*
PFP99
NOMESCO Finland
Percutaneous plastic repair of artery of lower leg
+∞
9.4
9
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
7.8
9.4
21
29
QCB10
NOMESCO Finland
Major dressing of wound of skin of upper limb
8.8
9.2
19
23
SPAT1216
SPAT
Assessment of functional ability
2.7
9.1
57
245
J04AB02
ATC
rifampicin; systemic
38.1
9.1
11
*
V03AE02
ATC
sevelamer; oral
38.1
9.1
11
*
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.8
9.0
21
47
ZX120
NOMESCO Finland
Intravenous
3.2
9.0
38
131
C02AC05
ATC
moxonidine; oral
4.2
8.8
24
61
Z95.1
ICD-10 Finland
Presence of aortocoronary bypass graft
4.2
8.8
24
61
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
8.8
144
939
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.2
8.8
128
797
SPAT1211
SPAT
Application of soft bandage
3.4
8.8
34
111
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
3.0
8.8
42
156
A10BB01
ATC
glibenclamide; oral
4.1
8.7
25
66
QD6S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in foot
51.8
8.7
10
*
PD3AT
NOMESCO Finland
Pelvic artery PTA
51.8
8.7
10
*
NHS99
NOMESCO Finland
Other operation for infection of tendon, joint or bone of ankle or foot
51.8
8.7
10
*
M86.8
ICD-10 Finland
Other osteomyelitis
51.8
8.7
10
*
ZPB22
NOMESCO Finland
Autograft of vein
51.8
8.7
10
*
J01XX08
ATC
linezolid; systemic
51.8
8.7
10
*
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
8.7
8.7
18
22
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.6
8.7
57
250
SPAT1263
SPAT
Sampling
2.2
8.7
123
756
C10AA01
ATC
simvastatin; oral
2.2
8.7
135
861
I83.0
ICD-10 Finland
Varicose veins of lower extremities with ulcer
9.5
8.7
17
19
A10BB12
ATC
glimepiride; oral
3.2
8.6
36
123
B05DB
ATC
Hypertonic solutions
28.6
8.5
11
*
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
3.9
8.5
26
72
EBA15
NOMESCO Finland
Extraction of multiple teeth
4.7
8.5
20
45
M86.1
ICD-10 Finland
Other acute osteomyelitis
92.9
8.5
9
*
L98
ICPC
Acquired deformity of limb
92.9
8.5
9
*
D06AX01
ATC
fusidic acid; topical
3.3
8.4
34
114
NGQ10
NOMESCO Finland
Exarticulation of knee
+∞
8.4
8
*
NHQ48
NOMESCO Finland
Revision of amputation of toe
+∞
8.4
8
*
T87.0
ICD-10 Finland
Complications of reattached (part of) upper extremity
+∞
8.4
8
*
T81.9
ICD-10 Finland
Unspecified complication of procedure
+∞
8.4
8
*
Y84
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
+∞
8.4
8
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.4
8.3
32
104
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.4
8.3
31
99
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
2.2
8.2
88
481
V03AE01
ATC
polystyrene sulfonate; oral
12.2
8.2
14
12
QCB05
NOMESCO Finland
Revision of wound of skin of upper limb
17.9
8.2
12
7
E10.8
ICD-10 Finland
Type 1 diabetes mellitus, With unspecified complications
10.5
8.1
15
15
N18.0
ICD-10 Finland
End-stage renal disease
34.5
8.1
10
*
A10AD04
ATC
insulin lispro; parenteral
34.5
8.1
10
*
196
Kela drug reimbursment
Paricalcitol and cinacalcet
34.5
8.1
10
*
PEH57
NOMESCO Finland
Bypass from femoral artery to popliteal artery below knee
34.5
8.1
10
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.5
8.1
58
265
SPAT1225
SPAT
Implementation of podiatry rehabilitation plan
7.6
8.1
18
25
E10.6
ICD-10 Finland
Type 1 diabetes mellitus, With other specified complications
22.9
8.1
11
5
B05DA
ATC
Isotonic solutions
22.9
8.1
11
5
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
4.2
8.1
22
56
I25.0
ICD-10 Finland
Atherosclerotic cardiovascular disease, so described
3.3
8.1
32
106
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
8.2
8.0
17
22
201
Kela drug reimbursment
Chronic cardiac insufficiency
3.3
8.0
31
101
S11
ICPC
Skin infection post-traumatic
13.6
8.0
13
10
F32.9
ICD-10 Finland
Depressive episode, unspecified
3.0
7.9
37
135
S17
ICPC
Abrasion/scratch/blister
8.9
7.9
16
19
177
Kela drug reimbursment
Insulin glargine 300 U / ml
7.3
7.9
18
26
C01DA14
ATC
isosorbide mononitrate; oral
2.4
7.9
67
331
C01AA05
ATC
digoxin; systemic
2.9
7.9
39
147
I48
ICD-10 Finland
Atrial fibrillation and flutter
2.2
7.9
83
450
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
4.6
7.8
19
44
H36.09*E11.3
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic retinopathy
15.6
7.8
12
8
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
15.6
7.8
12
8
M79.6
ICD-10 Finland
Pain in limb
2.1
7.8
120
754
JAK10
NOMESCO Finland
Laparotomy and insertion of peritoneal dialysis catheter
46.4
7.8
9
*
P19
ICPC
Drug abuse
46.4
7.8
9
*
WX002
NOMESCO Finland
Sedation and analgesia
2.4
7.7
59
278
A02BC01
ATC
omeprazole; systemic
2.2
7.7
84
462
TNX34
NOMESCO Finland
Major custom molded cast, unspecified region
19.1
7.7
11
6
NH1CG
NOMESCO Finland
Ankle and foot extensive MRI examination with high intensity magnet
19.1
7.7
11
6
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
2.7
7.6
46
193
N25.8
ICD-10 Finland
Other disorders resulting from impaired renal tubular function
25.9
7.6
10
*
TNH31
NOMESCO Finland
Prefabricated orthosis, ankle or foot
25.9
7.6
10
*
ZXA10
NOMESCO Finland
Bilateral
2.4
7.6
65
322
TNX33
NOMESCO Finland
Custom moulded cast, unspecified region
4.1
7.6
21
54
N06AX21
ATC
duloxetine; oral
3.0
7.6
36
133
CKD05
NOMESCO Finland
Puncture of vitreous body with injection of medication
3.7
7.5
24
69
M14.6*E10.6
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic neuropathic
82.3
7.5
8
*
I79.2*E10.5
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic peripheral angiopathy
82.3
7.5
8
*
PFH66
NOMESCO Finland
Bypass from femoral or popliteal artery to dorsal artery of foot
82.3
7.5
8
*
PWE00
NOMESCO Finland
Reoperation for deep haemorrhage in surgery of peripheral vessels and lymphatic system
82.3
7.5
8
*
L04AA06
ATC
mycophenolic acid; systemic
11.3
7.4
13
12
L08.8
ICD-10 Finland
Other specified local infections of skin and subcutaneous tissue
6.1
7.4
19
33
FN1YT
NOMESCO Finland
Percutaneous insertion of coronary artery stent
3.5
7.3
26
80
T82.7
ICD-10 Finland
Infection and inflammatory reaction due to other cardiac and vascular devices, implants and grafts
+∞
7.3
7
*
NHW99
NOMESCO Finland
Other reoperation in surgery of ankle or foot
+∞
7.3
7
*
T87.1
ICD-10 Finland
Complications of reattached (part of) lower extremity
+∞
7.3
7
*
Y83.1
ICD-10 Finland
Surgical operation with implant of artificial internal device as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
+∞
7.3
7
*
PWG00
NOMESCO Finland
Reoperation on peripheral vessels for thrombosis or embolism
+∞
7.3
7
*
Y98
ICD-10 Finland
Lifestyle-related condition
+∞
7.3
7
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.6
7.3
25
75
TNX39
NOMESCO Finland
Other orthopedic bandage, unspecified region
16.3
7.3
11
7
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
7.3
83
463
I21.41
ICD-10 Finland
Acute subendocardial infarction stenosed coronary artery
3.4
7.2
27
86
N05AA02
ATC
levomepromazine; systemic
4.3
7.2
19
47
M86.4
ICD-10 Finland
Chronic osteomyelitis with draining sinus
30.9
7.2
9
*
X44
ICD-10 Finland
Accidental poisoning by and exposure to other and unspecified drugs, medicaments and biological substances
12.5
7.2
12
10
I25.9
ICD-10 Finland
Chronic ischaemic heart disease, unspecified
2.6
7.1
45
193
WW500
NOMESCO Finland
Blood transfusion
4.1
7.1
20
52
ZXE40
NOMESCO Finland
More than seven and less than nine hours
10.5
7.1
13
13
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.1
7.1
83
467
NF1AA
NOMESCO Finland
Hip X-ray examination
3.1
7.1
31
109
E0000UV, ,
ATC
2.0
7.0
109
681
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.0
7.0
106
657
TNG34
NOMESCO Finland
Major custom moulded orthopaedic cast, knee or lower leg
14.3
7.0
11
8
Z3231
NOMESCO Finland
Registered nurse
2.1
6.9
81
455
E11.4
ICD-10 Finland
Type 2 diabetes mellitus, with neurological complications
6.0
6.9
18
32
J01MA14
ATC
moxifloxacin; systemic
2.9
6.9
34
128
NH1BG
NOMESCO Finland
Ankle and foot MRI examination with high intensity magnet
9.7
6.9
13
14
A10BA02
ATC
metformin; oral
2.1
6.9
95
568
I25.2
ICD-10 Finland
Old myocardial infarction
3.0
6.8
32
117
X57
ICD-10 Finland
Unspecified privation
7.5
6.8
15
21
XF600
NOMESCO Finland
Bloodpressure measurement
3.3
6.8
26
84
N17.8
ICD-10 Finland
Other acute renal failure
17.2
6.8
10
6
D03BA02
ATC
collagenase; topical
41.1
6.8
8
*
NHG20
NOMESCO Finland
Fusion of talocrural joint
41.1
6.8
8
*
QXB10
NOMESCO Finland
Exchange of dressing for large skin wound, unspecified location
41.1
6.8
8
*
L70
ICPC
Infection of musculoskeletal system
41.1
6.8
8
*
N30.0
ICD-10 Finland
Acute cystitis
2.6
6.8
43
185
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
3.0
6.8
31
112
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.2
6.7
66
345
A07AA09
ATC
vancomycin; oral
23.2
6.7
9
*
Z94.0
ICD-10 Finland
Kidney transplant status
23.2
6.7
9
*
N17.0
ICD-10 Finland
Acute renal failure with tubular necrosis
23.2
6.7
9
*
T93.2
ICD-10 Finland
Sequelae of other fractures of lower limb
23.2
6.7
9
*
H36.00
ICD-10 Finland
Diabetic background retinopathy
8.1
6.7
14
18
W19
ICD-10 Finland
Unspecified fall
2.8
6.7
36
142
TNX30
NOMESCO Finland
Soft bandage, unspecified region
12.7
6.6
11
9
PD4AD
NOMESCO Finland
CT of lower extremity arteries
12.7
6.6
11
9
B01AC07
ATC
dipyridamole; systemic
3.4
6.6
24
75
H3600, E113,
ICD-10 Finland
10.4
6.6
12
12
S91.1
ICD-10 Finland
Open wound of toe(s) without damage to nail
10.4
6.6
12
12
G63.2*E11.4
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic polyneuropathy
10.4
6.6
12
12
Z3226
NOMESCO Finland
Physiotherapist
2.4
6.5
52
249
S01
ICPC
Pain/tenderness of skin
3.9
6.5
19
51
QDE99
NOMESCO Finland
Other excision or repair of lesion of skin of lower limb
71.5
6.5
7
*
QDG00
NOMESCO Finland
Debridement of bedsore of lower limb
71.5
6.5
7
*
K92.1
ICD-10 Finland
Melaena
3.5
6.4
22
66
C09AA05
ATC
ramipril; oral
2.0
6.4
87
514
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
5.8
6.4
17
31
4402A
ICD-9 Finland
Atherosclerosis, Of native arteries of the extremities
9.6
6.4
12
13
Z49.0
ICD-10 Finland
Preparatory care for dialysis
18.6
6.3
9
5
NH2AA
NOMESCO Finland
Heel X-ray examination
18.6
6.3
9
5
E10.1
ICD-10 Finland
Type 1 diabetes mellitus, With ketoacidosis
18.6
6.3
9
5
S72.0
ICD-10 Finland
Fracture of neck of femur
3.6
6.3
21
62
PWC00
NOMESCO Finland
Reoperation for deep infection in surgery of peripheral vessels and lymphatic system
+∞
6.3
6
*
NHQ20
NOMESCO Finland
Amputation of ankle
+∞
6.3
6
*
L02.2
ICD-10 Finland
Cutaneous abscess, furuncle and carbuncle of trunk
4.2
6.3
17
43
R5110, ,
SPAT
2.9
6.3
30
111
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
27.4
6.3
8
*
QBB05
NOMESCO Finland
Revision of wound of skin of trunk
27.4
6.3
8
*
C07AG02
ATC
carvedilol; oral
3.2
6.3
25
83
C07AB02
ATC
metoprolol; systemic
2.1
6.3
69
377
Z01.8
ICD-10 Finland
Other specified special examinations
2.2
6.2
64
340
R73.9
ICD-10 Finland
Hyperglycaemia, unspecified
4.3
6.2
16
39
S70.0
ICD-10 Finland
Contusion of hip
4.3
6.2
16
39
346
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
3.4
6.2
22
68
A06AD11
ATC
lactulose; oral
2.3
6.1
52
255
A41.8
ICD-10 Finland
Other specified sepsis
8.9
6.1
12
14
B99
ICD-10 Finland
Other and unspecified infectious diseases
7.0
6.1
14
21
WW200
NOMESCO Finland
Immunization
7.0
6.1
14
21
XCK10
NOMESCO Finland
Photography of fundus of eye
2.6
6.1
39
168
A10AD01
ATC
insulin (human); parenteral
5.8
6.1
16
29
TNX32
NOMESCO Finland
Custom moulded splint, unspecified region
3.9
6.0
18
49
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
2.1
6.0
72
405
FNA01
NOMESCO Finland
Anastomosis to coronary artery from internal mammary artery, one distal anastamosis
3.4
6.0
22
69
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Atherosclerosis of arteries of extremities
I70.2 [45538421]
I70.2 [45538421]
3.5e+00
4.4e+00
5.0e+00
—
5.2e+00
4.2e+00
3.4e+00
cases:30.53%
controls:1.30%
cases:40.84%
controls:0.88%
cases:35.11%
controls:0.38%
—
—
cases:28.85%
controls:0.23%
cases:34.74%
controls:0.83%
cases:33.73%
controls:1.67%
80
34
182
2586
107
23
155
2597
92
10
170
2610
—
73
6
180
2603
74
21
139
2510
56
36
110
2115
Vascular Surgery
77 [38004496]
77 [38004496]
2.8e+00
4.0e+00
4.6e+00
—
4.0e+00
3.3e+00
2.6e+00
cases:27.48%
controls:2.33%
cases:33.59%
controls:0.88%
cases:21.76%
controls:0.27%
—
—
cases:16.21%
controls:0.34%
cases:21.60%
controls:0.99%
cases:28.31%
controls:2.98%
72
61
190
2559
88
23
174
2597
57
7
205
2613
—
41
9
212
2600
46
25
167
2506
47
64
119
2087
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
SPAT1148 [2001700249]
2.4e+00
3.2e+00
3.6e+00
—
2.8e+00
3.6e+00
2.3e+00
cases:19.47%
controls:2.06%
cases:17.18%
controls:0.80%
cases:8.02%
controls:0.23%
—
—
cases:6.72%
controls:0.42%
cases:17.37%
controls:0.59%
cases:19.28%
controls:2.28%
51
54
211
2566
45
21
217
2599
21
6
241
2614
—
17
11
236
2598
37
15
176
2516
32
49
134
2102
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
E11.7 [45561950]
2.8e+00
2.9e+00
3.5e+00
1.0e+50
3.0e+00
2.7e+00
2.8e+00
cases:15.27%
controls:1.07%
cases:11.45%
controls:0.69%
cases:6.11%
controls:0.19%
cases:3.82%
controls:0.00%
cases:3.56%
controls:0.19%
cases:12.68%
controls:0.99%
cases:18.67%
controls:1.35%
40
28
222
2592
30
18
232
2602
16
5
246
2615
10
0
252
2620
9
5
244
2604
27
25
186
2506
31
29
135
2122
Ulcer of lower limb, not elsewhere classified
L97 [45591659]
L97 [45591659]
3.4e+00
4.4e+00
—
1.0e+50
—
4.2e+00
3.4e+00
cases:13.36%
controls:0.50%
cases:16.41%
controls:0.23%
—
—
cases:4.20%
controls:0.00%
—
—
cases:12.21%
controls:0.20%
cases:15.06%
controls:0.60%
35
13
227
2607
43
6
219
2614
—
11
0
251
2620
—
26
5
187
2526
25
13
141
2138
Nephrology
39 [38004479]
39 [38004479]
2.5e+00
2.9e+00
2.8e+00
—
2.8e+00
2.3e+00
2.1e+00
cases:10.31%
controls:0.95%
cases:9.54%
controls:0.57%
cases:6.11%
controls:0.38%
—
—
cases:4.74%
controls:0.31%
cases:7.98%
controls:0.83%
cases:10.84%
controls:1.39%
27
25
235
2595
25
15
237
2605
16
10
246
2610
—
12
8
241
2601
17
21
196
2510
18
30
148
2121
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
1.9e+00
2.5e+00
4.0e+00
1.0e+50
3.3e+00
2.1e+00
1.3e+00
cases:17.94%
controls:3.17%
cases:21.76%
controls:2.29%
cases:11.07%
controls:0.23%
cases:11.07%
controls:0.00%
cases:10.67%
controls:0.42%
cases:12.68%
controls:1.82%
cases:21.08%
controls:6.51%
47
83
215
2537
57
60
205
2560
29
6
233
2614
29
0
233
2620
27
11
226
2598
27
46
186
2485
35
140
131
2011
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
2.5e+00
3.0e+00
3.2e+00
—
2.2e+00
2.4e+00
1.6e+00
cases:13.74%
controls:1.34%
cases:15.65%
controls:0.95%
cases:7.63%
controls:0.34%
—
—
cases:3.56%
controls:0.42%
cases:10.33%
controls:1.03%
cases:14.46%
controls:3.30%
36
35
226
2585
41
25
221
2595
20
9
242
2611
—
9
11
244
2598
22
26
191
2505
24
71
142
2080
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
2.1e+00
2.3e+00
2.8e+00
—
2.9e+00
2.5e+00
2.0e+00
cases:21.37%
controls:3.36%
cases:13.74%
controls:1.53%
cases:7.63%
controls:0.50%
—
—
cases:7.11%
controls:0.42%
cases:15.96%
controls:1.46%
cases:21.69%
controls:3.72%
56
88
206
2532
36
40
226
2580
20
13
242
2607
—
18
11
235
2598
34
37
179
2494
36
80
130
2071
Internal Medicine
11 [38004456]
11 [38004456]
1.5e+00
1.7e+00
2.1e+00
4.3e+00
2.2e+00
1.5e+00
1.2e+00
cases:57.63%
controls:23.24%
cases:38.93%
controls:10.08%
cases:11.45%
controls:1.60%
cases:12.21%
controls:0.19%
cases:13.83%
controls:1.72%
cases:30.99%
controls:9.13%
cases:51.81%
controls:24.04%
151
609
111
2011
102
264
160
2356
30
42
232
2578
32
5
230
2615
35
45
218
2564
66
231
147
2300
86
517
80
1634
Chronic ulcer skin
S97 [2002001061]
S97 [2002001061]
3.6e+00
3.4e+00
—
—
—
3.9e+00
3.2e+00
cases:14.89%
controls:0.46%
cases:11.45%
controls:0.42%
—
—
—
—
—
—
cases:15.02%
controls:0.36%
cases:18.07%
controls:0.93%
39
12
223
2608
30
11
232
2609
—
—
—
32
9
181
2522
30
20
136
2131
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
1.2e+00
2.1e+00
3.5e+00
—
4.0e+00
1.7e+00
1.2e+00
cases:15.65%
controls:5.31%
cases:14.89%
controls:2.06%
cases:8.02%
controls:0.27%
—
—
cases:9.49%
controls:0.19%
cases:8.92%
controls:1.70%
cases:17.47%
controls:6.23%
41
139
221
2481
39
54
223
2566
21
7
241
2613
—
24
5
229
2604
19
43
194
2488
29
134
137
2017
Outpatient Hospital
22 [8756]
22 [8756]
1.5e+00
2.3e+00
3.3e+00
—
3.3e+00
2.0e+00
1.1e+00
cases:61.07%
controls:25.53%
cases:43.13%
controls:7.06%
cases:22.52%
controls:1.11%
—
—
cases:18.58%
controls:0.84%
cases:29.11%
controls:5.25%
cases:44.58%
controls:20.69%
160
669
102
1951
113
185
149
2435
59
29
203
2591
—
47
22
206
2587
62
133
151
2398
74
445
92
1706
Major dressing of wound of skin of lower limb
QDB10 [2001309970]
QDB10 [2001309970]
4.3e+00
4.7e+00
—
1.0e+50
—
—
4.4e+00
cases:18.32%
controls:0.31%
cases:17.56%
controls:0.19%
—
—
cases:2.67%
controls:0.00%
—
—
—
—
cases:18.07%
controls:0.28%
48
8
214
2612
46
5
216
2615
—
7
0
255
2620
—
—
30
6
136
2145
General Surgery
2 [38004447]
2 [38004447]
1.3e+00
2.0e+00
3.2e+00
1.0e+50
3.4e+00
2.1e+00
1.2e+00
cases:45.80%
controls:19.27%
cases:32.44%
controls:5.88%
cases:19.85%
controls:0.95%
cases:21.76%
controls:0.00%
cases:14.62%
controls:0.57%
cases:28.17%
controls:4.62%
cases:37.95%
controls:15.39%
120
505
142
2115
85
154
177
2466
52
25
210
2595
57
0
205
2620
37
15
216
2594
60
117
153
2414
63
331
103
1820
General Practice
1 [38004446]
1 [38004446]
1.3e+00
2.2e+00
3.4e+00
1.0e+50
3.4e+00
1.7e+00
1.0e+00
cases:39.31%
controls:14.54%
cases:37.40%
controls:6.34%
cases:17.18%
controls:0.69%
cases:16.03%
controls:0.00%
cases:24.51%
controls:1.07%
cases:27.70%
controls:6.24%
cases:40.96%
controls:19.85%
103
381
159
2239
98
166
164
2454
45
18
217
2602
42
0
220
2620
62
28
191
2581
59
158
154
2373
68
427
98
1724
Inpatient Visit
IP [9201]
IP [9201]
1.3e+00
1.9e+00
3.6e+00
1.0e+50
3.4e+00
1.9e+00
9.3e-01
cases:14.89%
controls:4.62%
cases:13.74%
controls:2.29%
cases:9.16%
controls:0.27%
cases:1.91%
controls:0.00%
cases:9.49%
controls:0.34%
cases:14.08%
controls:2.33%
cases:16.87%
controls:7.44%
39
121
223
2499
36
60
226
2560
24
7
238
2613
5
0
257
2620
24
9
229
2600
30
59
183
2472
28
160
138
1991
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
22664-7 [3020779]
1.7e+00
2.3e+00
2.7e+00
—
2.6e+00
2.1e+00
1.5e+00
cases:8.78%
controls:1.68%
cases:9.16%
controls:0.95%
cases:3.44%
controls:0.23%
—
—
cases:3.56%
controls:0.27%
cases:6.10%
controls:0.79%
cases:10.84%
controls:2.60%
23
44
239
2576
24
25
238
2595
9
6
253
2614
—
9
7
244
2602
13
20
200
2511
18
56
148
2095
Physical Medicine And Rehabilitation
25 [38004468]
25 [38004468]
1.4e+00
2.0e+00
2.1e+00
1.0e+50
3.0e+00
2.4e+00
2.0e+00
cases:17.94%
controls:5.19%
cases:13.36%
controls:2.10%
cases:4.58%
controls:0.57%
cases:3.05%
controls:0.00%
cases:5.14%
controls:0.27%
cases:17.37%
controls:1.82%
cases:29.52%
controls:5.16%
47
136
215
2484
35
55
227
2565
12
15
250
2605
8
0
254
2620
13
7
240
2602
37
46
176
2485
49
111
117
2040
Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]
E11.8 [45561951]
1.9e+00
2.4e+00
2.8e+00
1.0e+50
2.7e+00
1.8e+00
1.3e+00
cases:11.07%
controls:1.76%
cases:8.40%
controls:0.84%
cases:3.05%
controls:0.19%
cases:3.05%
controls:0.00%
cases:2.77%
controls:0.19%
cases:4.69%
controls:0.83%
cases:9.04%
controls:2.65%
29
46
233
2574
22
22
240
2598
8
5
254
2615
8
0
254
2620
7
5
246
2604
10
21
203
2510
15
57
151
2094
Outpatient Visit
OP [9202]
OP [9202]
7.0e-01
1.2e+00
1.8e+00
4.2e+00
1.9e+00
1.5e+00
1.2e+00
cases:81.68%
controls:68.85%
cases:75.95%
controls:49.01%
cases:40.08%
controls:9.62%
cases:25.57%
controls:0.50%
cases:39.92%
controls:9.20%
cases:80.28%
controls:48.20%
cases:92.17%
controls:77.31%
214
1804
48
816
199
1284
63
1336
105
252
157
2368
67
13
195
2607
101
240
152
2369
171
1220
42
1311
153
1663
13
488
Laceration/cut
S18 [2002000983]
S18 [2002000983]
1.3e+00
2.1e+00
2.4e+00
—
3.0e+00
2.3e+00
1.4e+00
cases:21.76%
controls:6.76%
cases:19.47%
controls:2.90%
cases:7.25%
controls:0.69%
—
—
cases:7.51%
controls:0.38%
cases:20.19%
controls:2.57%
cases:29.52%
controls:9.44%
57
177
205
2443
51
76
211
2544
19
18
243
2602
—
19
10
234
2599
43
65
170
2466
49
203
117
1948
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
2.4e+00
3.9e+00
—
—
—
3.6e+00
2.6e+00
cases:20.61%
controls:2.25%
cases:22.90%
controls:0.61%
—
—
—
—
—
—
cases:20.19%
controls:0.71%
cases:21.08%
controls:1.95%
54
59
208
2561
60
16
202
2604
—
—
—
43
18
170
2513
35
42
131
2109
Other diagnostic examination of periferal vessel
XPX99 [2001309755]
XPX99 [2001309755]
3.0e+00
3.6e+00
—
—
—
3.2e+00
2.6e+00
cases:10.31%
controls:0.57%
cases:8.78%
controls:0.27%
—
—
—
—
—
—
cases:5.63%
controls:0.24%
cases:9.04%
controls:0.70%
27
15
235
2605
23
7
239
2613
—
—
—
12
6
201
2525
15
15
151
2136
Emergency Room Visit
ER [9203]
ER [9203]
1.4e+00
2.1e+00
3.1e+00
—
2.8e+00
1.6e+00
1.2e+00
cases:66.79%
controls:33.28%
cases:54.20%
controls:12.37%
cases:24.81%
controls:1.41%
—
—
cases:20.16%
controls:1.46%
cases:36.62%
controls:10.04%
cases:62.65%
controls:32.64%
175
872
87
1748
142
324
120
2296
65
37
197
2583
—
51
38
202
2571
78
254
135
2277
104
702
62
1449
Inpatient Hospital
21 [8717]
21 [8717]
1.5e+00
2.1e+00
2.8e+00
—
3.2e+00
1.7e+00
1.1e+00
cases:68.70%
controls:33.89%
cases:51.53%
controls:11.45%
cases:27.10%
controls:2.14%
—
—
cases:27.67%
controls:1.61%
cases:37.56%
controls:9.84%
cases:53.01%
controls:28.22%
180
888
82
1732
135
300
127
2320
71
56
191
2564
—
70
42
183
2567
80
249
133
2282
88
607
78
1544
Type 1 diabetes mellitus, With multiple complications
E10.7 [45571655]
E10.7 [45571655]
2.4e+00
2.4e+00
2.8e+00
1.0e+50
—
2.3e+00
2.3e+00
cases:9.54%
controls:0.92%
cases:7.25%
controls:0.69%
cases:3.82%
controls:0.23%
cases:2.67%
controls:0.00%
—
—
cases:7.04%
controls:0.75%
cases:7.23%
controls:0.79%
25
24
237
2596
19
18
243
2602
10
6
252
2614
7
0
255
2620
—
15
19
198
2512
12
17
154
2134
Foot and toes X-ray examination
NH3AA [2001308267]
NH3AA [2001308267]
2.7e+00
4.1e+00
—
1.0e+50
—
3.0e+00
2.4e+00
cases:9.16%
controls:0.65%
cases:10.69%
controls:0.19%
—
—
cases:3.82%
controls:0.00%
—
—
cases:4.69%
controls:0.24%
cases:7.83%
controls:0.79%
24
17
238
2603
28
5
234
2615
—
10
0
252
2620
—
10
6
203
2525
13
17
153
2134
Endocrinology
46 [38004485]
46 [38004485]
1.8e+00
2.2e+00
2.3e+00
—
2.3e+00
1.9e+00
1.6e+00
cases:14.12%
controls:2.56%
cases:10.69%
controls:1.26%
cases:3.44%
controls:0.34%
—
—
cases:1.98%
controls:0.19%
cases:8.45%
controls:1.34%
cases:13.25%
controls:3.11%
37
67
225
2553
28
33
234
2587
9
9
253
2611
—
5
5
248
2604
18
34
195
2497
22
67
144
2084
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
1.6e+00
2.0e+00
2.5e+00
—
3.0e+00
1.7e+00
1.2e+00
cases:11.07%
controls:2.40%
cases:10.69%
controls:1.64%
cases:4.96%
controls:0.42%
—
—
cases:4.35%
controls:0.23%
cases:8.45%
controls:1.58%
cases:11.45%
controls:3.91%
29
63
233
2557
28
43
234
2577
13
11
249
2609
—
11
6
242
2603
18
40
195
2491
19
84
147
2067
flucloxacillin; oral, parenteral
J01CF05 [21602857]
J01CF05 [21602857]
2.7e+00
2.9e+00
—
—
—
3.3e+00
2.9e+00
cases:4.20%
controls:0.31%
cases:3.44%
controls:0.19%
—
—
—
—
—
—
cases:5.16%
controls:0.20%
cases:6.63%
controls:0.37%
11
8
251
2612
9
5
253
2615
—
—
—
11
5
202
2526
11
8
155
2143
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
1.5e+00
2.0e+00
2.9e+00
1.0e+50
2.8e+00
1.6e+00
9.0e-01
cases:13.36%
controls:3.40%
cases:16.03%
controls:2.44%
cases:6.49%
controls:0.38%
cases:9.54%
controls:0.00%
cases:7.11%
controls:0.46%
cases:10.80%
controls:2.37%
cases:21.08%
controls:9.76%
35
89
227
2531
42
64
220
2556
17
10
245
2610
25
0
237
2620
18
12
235
2597
23
60
190
2471
35
210
131
1941
Atherosclerotic heart disease
I25.1 [45596196]
I25.1 [45596196]
1.5e+00
1.7e+00
2.9e+00
1.0e+50
2.7e+00
1.6e+00
1.3e+00
cases:20.99%
controls:5.80%
cases:14.12%
controls:2.98%
cases:8.02%
controls:0.50%
cases:2.67%
controls:0.00%
cases:7.11%
controls:0.54%
cases:12.68%
controls:2.84%
cases:22.89%
controls:7.30%
55
152
207
2468
37
78
225
2542
21
13
241
2607
7
0
255
2620
18
14
235
2595
27
72
186
2459
38
157
128
1994
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
1.5e+00
2.1e+00
2.4e+00
—
2.8e+00
1.5e+00
1.2e+00
cases:62.21%
controls:27.75%
cases:43.13%
controls:8.74%
cases:11.45%
controls:1.11%
—
—
cases:13.44%
controls:0.92%
cases:27.23%
controls:7.70%
cases:54.22%
controls:25.94%
163
727
99
1893
113
229
149
2391
30
29
232
2591
—
34
24
219
2585
58
195
155
2336
90
558
76
1593
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
2.3e+00
3.3e+00
—
—
—
3.5e+00
2.2e+00
cases:16.41%
controls:1.87%
cases:16.79%
controls:0.76%
—
—
—
—
—
—
cases:10.33%
controls:0.36%
cases:16.87%
controls:2.19%
43
49
219
2571
44
20
218
2600
—
—
—
22
9
191
2522
28
47
138
2104
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
1.4e+00
2.0e+00
2.2e+00
—
3.0e+00
1.5e+00
1.2e+00
cases:25.57%
controls:8.02%
cases:16.03%
controls:2.63%
cases:4.96%
controls:0.57%
—
—
cases:6.72%
controls:0.34%
cases:10.33%
controls:2.61%
cases:21.08%
controls:7.16%
67
210
195
2410
42
69
220
2551
13
15
249
2605
—
17
9
236
2600
22
66
191
2465
35
154
131
1997
clindamycin; oral, parenteral
J01FF01 [21602985]
J01FF01 [21602985]
2.5e+00
3.3e+00
—
—
—
3.1e+00
2.4e+00
cases:27.10%
controls:3.02%
cases:17.94%
controls:0.84%
—
—
—
—
—
—
cases:14.08%
controls:0.71%
cases:23.49%
controls:2.74%
71
79
191
2541
47
22
215
2598
—
—
—
30
18
183
2513
39
59
127
2092
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
1.3e+00
1.7e+00
2.1e+00
—
2.8e+00
1.8e+00
1.1e+00
cases:18.70%
controls:5.76%
cases:12.60%
controls:2.48%
cases:4.20%
controls:0.53%
—
—
cases:4.35%
controls:0.27%
cases:11.27%
controls:2.13%
cases:19.28%
controls:7.35%
49
151
213
2469
33
65
229
2555
11
14
251
2606
—
11
7
242
2602
24
54
189
2477
32
158
134
1993
calcium carbonate
A02AC01 [21600065]
A02AC01 [21600065]
2.5e+00
2.7e+00
—
—
—
2.5e+00
3.1e+00
cases:4.20%
controls:0.34%
cases:2.67%
controls:0.19%
—
—
—
—
—
—
cases:3.29%
controls:0.28%
cases:4.82%
controls:0.23%
11
9
251
2611
7
5
255
2615
—
—
—
7
7
206
2524
8
5
158
2146
calcium carbonate; oral
A12AA04 [21600863]
A12AA04 [21600863]
2.5e+00
2.7e+00
—
—
—
2.5e+00
3.1e+00
cases:4.20%
controls:0.34%
cases:2.67%
controls:0.19%
—
—
—
—
—
—
cases:3.29%
controls:0.28%
cases:4.82%
controls:0.23%
11
9
251
2611
7
5
255
2615
—
—
—
7
7
206
2524
8
5
158
2146
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
N08.39*E11.2 [2000503133]
N08.39*E11.2 [2000503133]
2.6e+00
2.6e+00
—
—
—
2.6e+00
2.7e+00
cases:3.82%
controls:0.31%
cases:3.05%
controls:0.23%
—
—
—
—
—
—
cases:4.23%
controls:0.32%
cases:6.02%
controls:0.42%
10
8
252
2612
8
6
254
2614
—
—
—
9
8
204
2523
10
9
156
2142
alfacalcidol; oral, parenteral
A11CC03 [21600818]
A11CC03 [21600818]
3.0e+00
2.7e+00
—
—
—
2.1e+00
2.7e+00
cases:4.96%
controls:0.27%
cases:3.44%
controls:0.23%
—
—
—
—
—
—
cases:2.82%
controls:0.36%
cases:5.42%
controls:0.37%
13
7
249
2613
9
6
253
2614
—
—
—
6
9
207
2522
9
8
157
2143
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
620-5 [3007853]
2.4e+00
3.4e+00
—
1.0e+50
—
2.7e+00
2.0e+00
cases:16.03%
controls:1.76%
cases:20.23%
controls:0.80%
—
—
cases:7.63%
controls:0.00%
—
—
cases:11.74%
controls:0.91%
cases:16.87%
controls:2.70%
42
46
220
2574
53
21
209
2599
—
20
0
242
2620
—
25
23
188
2508
28
58
138
2093
Erysipelas
A46 [45561706]
A46 [45561706]
2.6e+00
2.9e+00
—
—
—
2.5e+00
2.4e+00
cases:16.79%
controls:1.49%
cases:14.12%
controls:0.88%
—
—
—
—
—
—
cases:6.10%
controls:0.51%
cases:17.47%
controls:1.91%
44
39
218
2581
37
23
225
2597
—
—
—
13
13
200
2518
29
41
137
2110
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
9.5e-01
1.4e+00
2.2e+00
—
2.4e+00
2.2e+00
1.3e+00
cases:14.50%
controls:6.18%
cases:5.34%
controls:1.37%
cases:2.29%
controls:0.27%
—
—
cases:2.37%
controls:0.23%
cases:7.51%
controls:0.87%
cases:15.06%
controls:4.74%
38
162
224
2458
14
36
248
2584
6
7
256
2613
—
6
6
247
2603
16
22
197
2509
25
102
141
2049
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
1.0e+00
1.5e+00
2.6e+00
—
2.7e+00
1.4e+00
8.6e-01
cases:18.70%
controls:7.71%
cases:16.03%
controls:4.05%
cases:9.16%
controls:0.73%
—
—
cases:9.88%
controls:0.73%
cases:15.49%
controls:4.19%
cases:25.30%
controls:12.51%
49
202
213
2418
42
106
220
2514
24
19
238
2601
—
25
19
228
2590
33
106
180
2425
42
269
124
1882
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
1.3e+00
1.8e+00
2.7e+00
1.0e+50
2.2e+00
1.1e+00
1.0e+00
cases:24.81%
controls:8.05%
cases:16.41%
controls:3.24%
cases:5.73%
controls:0.42%
cases:1.91%
controls:0.00%
cases:3.56%
controls:0.42%
cases:8.92%
controls:3.04%
cases:21.69%
controls:8.88%
65
211
197
2409
43
85
219
2535
15
11
247
2609
5
0
257
2620
9
11
244
2598
19
77
194
2454
36
191
130
1960
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
1.1e+00
1.8e+00
3.3e+00
1.0e+50
—
2.1e+00
1.8e+00
cases:15.65%
controls:5.80%
cases:9.16%
controls:1.68%
cases:6.11%
controls:0.23%
cases:1.91%
controls:0.00%
—
—
cases:7.51%
controls:1.03%
cases:21.08%
controls:4.14%
41
152
221
2468
24
44
238
2576
16
6
246
2614
5
0
257
2620
—
16
26
197
2505
35
89
131
2062
insulin aspart; parenteral
A10AD05 [21600733]
A10AD05 [21600733]
2.2e+00
2.0e+00
1.9e+00
—
1.3e+00
1.9e+00
1.9e+00
cases:19.47%
controls:2.67%
cases:17.94%
controls:2.75%
cases:3.05%
controls:0.46%
—
—
cases:2.77%
controls:0.80%
cases:16.90%
controls:3.00%
cases:21.08%
controls:3.95%
51
70
211
2550
47
72
215
2548
8
12
254
2608
—
7
21
246
2588
36
76
177
2455
35
85
131
2066
insulin aspart; parenteral
A10AB05 [21600719]
A10AB05 [21600719]
2.2e+00
2.0e+00
1.9e+00
—
1.3e+00
1.8e+00
1.9e+00
cases:19.47%
controls:2.67%
cases:17.56%
controls:2.75%
cases:3.05%
controls:0.46%
—
—
cases:2.77%
controls:0.80%
cases:16.43%
controls:3.00%
cases:21.08%
controls:3.95%
51
70
211
2550
46
72
216
2548
8
12
254
2608
—
7
21
246
2588
35
76
178
2455
35
85
131
2066
gabapentin; oral
N02BF01 [955005]
N02BF01 [955005]
1.6e+00
2.2e+00
2.2e+00
—
1.5e+00
2.1e+00
1.7e+00
cases:10.69%
controls:2.44%
cases:9.92%
controls:1.26%
cases:3.82%
controls:0.42%
—
—
cases:2.37%
controls:0.54%
cases:10.80%
controls:1.42%
cases:14.46%
controls:2.88%
28
64
234
2556
26
33
236
2587
10
11
252
2609
—
6
14
247
2595
23
36
190
2495
24
62
142
2089
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
1.6e+00
2.4e+00
2.8e+00
—
1.9e+00
1.6e+00
1.4e+00
cases:10.31%
controls:2.33%
cases:9.54%
controls:0.95%
cases:3.05%
controls:0.19%
—
—
cases:1.98%
controls:0.31%
cases:7.51%
controls:1.62%
cases:13.86%
controls:3.86%
27
61
235
2559
25
25
237
2595
8
5
254
2615
—
5
8
248
2601
16
41
197
2490
23
83
143
2068
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
8.0e-01
1.4e+00
3.3e+00
1.0e+50
2.2e+00
1.4e+00
6.5e-01
cases:21.76%
controls:11.07%
cases:22.52%
controls:6.49%
cases:12.21%
controls:0.53%
cases:6.49%
controls:0.00%
cases:8.70%
controls:1.03%
cases:17.37%
controls:5.10%
cases:29.52%
controls:17.90%
57
290
205
2330
59
170
203
2450
32
14
230
2606
17
0
245
2620
22
27
231
2582
37
129
176
2402
49
385
117
1766
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
N02AX02 [21604298]
1.1e+00
1.8e+00
2.0e+00
—
1.9e+00
1.8e+00
1.1e+00
cases:20.61%
controls:7.67%
cases:13.36%
controls:2.48%
cases:4.96%
controls:0.73%
—
—
cases:3.56%
controls:0.57%
cases:12.68%
controls:2.45%
cases:17.47%
controls:6.69%
54
201
208
2419
35
65
227
2555
13
19
249
2601
—
9
15
244
2594
27
62
186
2469
29
144
137
2007
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
1.3e+00
2.0e+00
3.3e+00
1.0e+50
—
1.7e+00
1.2e+00
cases:12.60%
controls:3.74%
cases:10.69%
controls:1.53%
cases:6.49%
controls:0.27%
cases:3.05%
controls:0.00%
—
—
cases:6.57%
controls:1.26%
cases:13.86%
controls:4.60%
33
98
229
2522
28
40
234
2580
17
7
245
2613
8
0
254
2620
—
14
32
199
2499
23
99
143
2052
Nursing episode
950 [44777714]
950 [44777714]
1.7e+00
1.4e+00
2.1e+00
—
1.6e+00
1.6e+00
1.1e+00
cases:10.31%
controls:2.10%
cases:6.11%
controls:1.56%
cases:4.58%
controls:0.57%
—
—
cases:3.56%
controls:0.73%
cases:8.92%
controls:1.94%
cases:10.24%
controls:3.72%
27
55
235
2565
16
41
246
2579
12
15
250
2605
—
9
19
244
2590
19
49
194
2482
17
80
149
2071
Exposure to unspecified factor
X59 [45756412]
X59 [45756412]
2.1e+00
2.6e+00
—
1.0e+50
—
3.2e+00
1.5e+00
cases:10.69%
controls:1.49%
cases:8.02%
controls:0.61%
—
—
cases:11.07%
controls:0.00%
—
—
cases:11.74%
controls:0.51%
cases:9.64%
controls:2.32%
28
39
234
2581
21
16
241
2604
—
29
0
233
2620
—
25
13
188
2518
16
50
150
2101
Urgent procedure
ZXD05 [2001311386]
ZXD05 [2001311386]
1.9e+00
2.9e+00
—
1.0e+50
—
2.7e+00
2.0e+00
cases:21.37%
controls:4.01%
cases:16.41%
controls:1.03%
—
—
cases:4.58%
controls:0.00%
—
—
cases:8.45%
controls:0.63%
cases:16.87%
controls:2.79%
56
105
206
2515
43
27
219
2593
—
12
0
250
2620
—
18
16
195
2515
28
60
138
2091
Limited function/disability (L)
L28 [2002000647]
L28 [2002000647]
1.7e+00
1.7e+00
2.1e+00
—
—
2.2e+00
1.7e+00
cases:10.31%
controls:2.02%
cases:6.49%
controls:1.26%
cases:2.67%
controls:0.34%
—
—
—
—
cases:9.39%
controls:1.11%
cases:18.07%
controls:3.81%
27
53
235
2567
17
33
245
2587
7
9
255
2611
—
—
20
28
193
2503
30
82
136
2069
Right side
ZXA00 [2001311346]
ZXA00 [2001311346]
1.4e+00
2.0e+00
—
1.0e+50
2.1e+00
2.9e+00
9.8e-01
cases:13.74%
controls:3.82%
cases:7.63%
controls:1.07%
—
—
cases:1.91%
controls:0.00%
cases:2.37%
controls:0.31%
cases:7.98%
controls:0.47%
cases:9.64%
controls:3.86%
36
100
226
2520
20
28
242
2592
—
5
0
257
2620
6
8
247
2601
17
12
196
2519
16
83
150
2068
Home Visit
OMOP4822459 [581476]
OMOP4822459 [581476]
1.6e+00
1.7e+00
1.8e+00
—
1.6e+00
1.5e+00
1.1e+00
cases:21.37%
controls:5.31%
cases:18.70%
controls:3.97%
cases:8.02%
controls:1.45%
—
—
cases:7.91%
controls:1.69%
cases:16.43%
controls:4.23%
cases:26.51%
controls:10.41%
56
139
206
2481
49
104
213
2516
21
38
241
2582
—
20
44
233
2565
35
107
178
2424
44
224
122
1927
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
2.5e-01
6.5e-01
2.1e+00
4.5e+00
2.1e+00
4.6e-01
1.6e-01
cases:34.35%
controls:28.89%
cases:37.40%
controls:23.78%
cases:27.86%
controls:4.58%
cases:22.90%
controls:0.34%
cases:29.25%
controls:4.71%
cases:34.27%
controls:24.77%
cases:48.80%
controls:44.77%
90
757
172
1863
98
623
164
1997
73
120
189
2500
60
9
202
2611
74
123
179
2486
73
627
140
1904
81
963
85
1188
furosemide; oral, parenteral
C03CA01 [21601518]
C03CA01 [21601518]
1.9e+00
1.9e+00
1.4e+00
—
1.4e+00
1.5e+00
1.3e+00
cases:37.02%
controls:8.21%
cases:33.59%
controls:6.91%
cases:9.16%
controls:2.48%
—
—
cases:7.11%
controls:1.92%
cases:24.88%
controls:6.99%
cases:31.33%
controls:11.30%
97
215
165
2405
88
181
174
2439
24
65
238
2555
—
18
50
235
2559
53
177
160
2354
52
243
114
1908
Assessment of need for aid
SPAT1229 [2001700330]
SPAT1229 [2001700330]
2.1e+00
2.7e+00
—
—
—
2.9e+00
1.6e+00
cases:4.96%
controls:0.65%
cases:4.20%
controls:0.31%
—
—
—
—
—
—
cases:4.23%
controls:0.24%
cases:4.82%
controls:0.98%
13
17
249
2603
11
8
251
2612
—
—
—
9
6
204
2525
8
21
158
2130
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
1.4e+00
2.0e+00
2.3e+00
—
2.6e+00
9.2e-01
9.6e-01
cases:14.12%
controls:4.08%
cases:11.83%
controls:1.72%
cases:2.29%
controls:0.23%
—
—
cases:3.95%
controls:0.31%
cases:6.10%
controls:2.53%
cases:16.87%
controls:7.21%
37
107
225
2513
31
45
231
2575
6
6
256
2614
—
10
8
243
2601
13
64
200
2467
28
155
138
1996
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
1.5e+00
2.2e+00
2.2e+00
—
1.9e+00
8.7e-01
1.4e+00
cases:22.14%
controls:5.84%
cases:15.65%
controls:2.02%
cases:2.67%
controls:0.31%
—
—
cases:2.77%
controls:0.42%
cases:4.23%
controls:1.82%
cases:21.69%
controls:6.37%
58
153
204
2467
41
53
221
2567
7
8
255
2612
—
7
11
246
2598
9
46
204
2485
36
137
130
2014
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
2.5e-01
6.4e-01
2.1e+00
4.4e+00
2.1e+00
4.4e-01
1.5e-01
cases:34.35%
controls:29.01%
cases:37.79%
controls:24.27%
cases:27.86%
controls:4.62%
cases:21.76%
controls:0.34%
cases:29.25%
controls:4.87%
cases:34.27%
controls:25.17%
cases:48.80%
controls:45.00%
90
760
172
1860
99
636
163
1984
73
121
189
2499
57
9
205
2611
74
127
179
2482
73
637
140
1894
81
968
85
1183
Heart failure, unspecified
I50.9 [45576879]
I50.9 [45576879]
2.1e+00
2.0e+00
2.9e+00
1.0e+50
1.7e+00
2.0e+00
9.1e-01
cases:12.98%
controls:1.76%
cases:9.92%
controls:1.49%
cases:4.20%
controls:0.23%
cases:1.91%
controls:0.00%
cases:2.37%
controls:0.42%
cases:6.57%
controls:0.91%
cases:9.04%
controls:3.86%
34
46
228
2574
26
39
236
2581
11
6
251
2614
5
0
257
2620
6
11
247
2598
14
23
199
2508
15
83
151
2068
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
1.0e+00
1.9e+00
3.4e+00
—
—
1.7e+00
1.0e+00
cases:18.32%
controls:7.60%
cases:19.08%
controls:3.47%
cases:12.60%
controls:0.46%
—
—
—
—
cases:11.74%
controls:2.37%
cases:21.69%
controls:8.93%
48
199
214
2421
50
91
212
2529
33
12
229
2608
—
—
25
60
188
2471
36
192
130
1959
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
1.0e+00
1.5e+00
2.0e+00
1.0e+50
2.4e+00
1.1e+00
1.0e+00
cases:11.07%
controls:4.31%
cases:10.31%
controls:2.48%
cases:3.44%
controls:0.46%
cases:1.91%
controls:0.00%
cases:3.16%
controls:0.31%
cases:6.10%
controls:2.17%
cases:12.65%
controls:4.83%
29
113
233
2507
27
65
235
2555
9
12
253
2608
5
0
257
2620
8
8
245
2601
13
55
200
2476
21
104
145
2047
Suture or treatment of traumatic wound
SPAT1149 [2001700250]
SPAT1149 [2001700250]
1.9e+00
2.7e+00
—
—
—
2.6e+00
1.8e+00
cases:9.92%
controls:1.64%
cases:6.87%
controls:0.50%
—
—
—
—
—
—
cases:6.10%
controls:0.47%
cases:8.43%
controls:1.44%
26
43
236
2577
18
13
244
2607
—
—
—
13
12
200
2519
14
31
152
2120
Chronic kidney disease, unspecified
N18.9 [45553438]
N18.9 [45553438]
2.0e+00
2.6e+00
—
—
3.0e+00
1.5e+00
1.4e+00
cases:7.25%
controls:1.07%
cases:6.87%
controls:0.53%
—
—
—
—
cases:3.56%
controls:0.19%
cases:3.76%
controls:0.83%
cases:6.63%
controls:1.72%
19
28
243
2592
18
14
244
2606
—
—
9
5
244
2604
8
21
205
2510
11
37
155
2114
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
1.9e-01
4.9e-01
1.9e+00
4.2e+00
1.9e+00
5.4e-01
2.6e-01
cases:31.30%
controls:27.44%
cases:29.01%
controls:19.96%
cases:19.47%
controls:3.59%
cases:14.89%
controls:0.27%
cases:19.76%
controls:3.68%
cases:28.64%
controls:19.00%
cases:45.78%
controls:39.52%
82
719
180
1901
76
523
186
2097
51
94
211
2526
39
7
223
2613
50
96
203
2513
61
481
152
2050
76
850
90
1301
Orthopedic Surgery
20 [38004465]
20 [38004465]
9.3e-01
1.6e+00
2.5e+00
—
2.0e+00
1.2e+00
6.6e-01
cases:28.63%
controls:13.66%
cases:20.99%
controls:5.23%
cases:6.87%
controls:0.61%
—
—
cases:5.93%
controls:0.80%
cases:14.08%
controls:4.70%
cases:25.30%
controls:14.88%
75
358
187
2262
55
137
207
2483
18
16
244
2604
—
15
21
238
2588
30
119
183
2412
42
320
124
1831
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
13317-3 [3019902]
2.0e+00
2.4e+00
—
—
—
2.4e+00
2.0e+00
cases:9.54%
controls:1.41%
cases:8.40%
controls:0.84%
—
—
—
—
—
—
cases:8.45%
controls:0.83%
cases:10.24%
controls:1.49%
25
37
237
2583
22
22
240
2598
—
—
—
18
21
195
2510
17
32
149
2119
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
1.3e+00
1.9e+00
—
—
2.5e+00
1.9e+00
1.2e+00
cases:16.41%
controls:5.11%
cases:7.63%
controls:1.26%
—
—
—
—
cases:2.77%
controls:0.23%
cases:8.92%
controls:1.38%
cases:12.65%
controls:4.32%
43
134
219
2486
20
33
242
2587
—
—
7
6
246
2603
19
35
194
2496
21
93
145
2058
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
9.1e-02
4.6e-01
1.9e+00
4.5e+00
1.9e+00
3.1e-01
5.7e-02
cases:34.73%
controls:32.71%
cases:39.31%
controls:29.05%
cases:30.15%
controls:6.30%
cases:25.19%
controls:0.38%
cases:30.43%
controls:6.09%
cases:36.15%
controls:29.36%
cases:51.20%
controls:49.79%
91
857
171
1763
103
761
159
1859
79
165
183
2455
66
10
196
2610
77
159
176
2450
77
743
136
1788
85
1071
81
1080
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
9.6e-02
4.5e-01
1.8e+00
4.5e+00
1.9e+00
2.9e-01
3.6e-02
cases:34.73%
controls:32.60%
cases:38.93%
controls:28.93%
cases:29.77%
controls:6.30%
cases:24.81%
controls:0.38%
cases:30.04%
controls:6.02%
cases:35.68%
controls:29.36%
cases:50.60%
controls:49.70%
91
854
171
1766
102
758
160
1862
78
165
184
2455
65
10
197
2610
76
157
177
2452
76
743
137
1788
84
1069
82
1082
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
9.7e-02
4.5e-01
1.8e+00
4.5e+00
1.9e+00
2.9e-01
4.0e-02
cases:34.73%
controls:32.56%
cases:38.93%
controls:28.93%
cases:29.77%
controls:6.26%
cases:24.81%
controls:0.38%
cases:30.04%
controls:6.06%
cases:35.68%
controls:29.28%
cases:50.60%
controls:49.60%
91
853
171
1767
102
758
160
1862
78
164
184
2456
65
10
197
2610
76
158
177
2451
76
741
137
1790
84
1067
82
1084
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
1.6e-01
4.8e-01
1.9e+00
4.3e+00
2.0e+00
3.2e-01
7.2e-02
cases:34.35%
controls:30.92%
cases:37.40%
controls:26.98%
cases:29.39%
controls:5.80%
cases:22.90%
controls:0.42%
cases:29.64%
controls:5.56%
cases:34.74%
controls:27.93%
cases:50.00%
controls:48.21%
90
810
172
1810
98
707
164
1913
77
152
185
2468
60
11
202
2609
75
145
178
2464
74
707
139
1824
83
1037
83
1114
Bacterial infection, unspecified
A49.9 [45590816]
A49.9 [45590816]
2.2e+00
2.3e+00
—
—
—
1.8e+00
2.2e+00
cases:8.78%
controls:1.03%
cases:4.58%
controls:0.46%
—
—
—
—
—
—
cases:4.69%
controls:0.83%
cases:12.65%
controls:1.63%
23
27
239
2593
12
12
250
2608
—
—
—
10
21
203
2510
21
35
145
2116
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
1.1e+00
1.5e+00
2.3e+00
—
1.8e+00
9.1e-01
8.6e-01
cases:15.65%
controls:5.95%
cases:12.60%
controls:3.05%
cases:4.20%
controls:0.46%
—
—
cases:3.56%
controls:0.61%
cases:10.33%
controls:4.43%
cases:22.29%
controls:10.79%
41
156
221
2464
33
80
229
2540
11
12
251
2608
—
9
16
244
2593
22
112
191
2419
37
232
129
1919
Foot/toe symptom/complaint
L17 [2002000641]
L17 [2002000641]
1.3e+00
1.9e+00
2.6e+00
—
—
1.6e+00
9.9e-01
cases:12.21%
controls:3.66%
cases:8.02%
controls:1.34%
cases:3.05%
controls:0.23%
—
—
—
—
cases:7.04%
controls:1.46%
cases:13.25%
controls:5.39%
32
96
230
2524
21
35
241
2585
8
6
254
2614
—
—
15
37
198
2494
22
116
144
2035
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
9.8e-01
1.3e+00
2.1e+00
—
2.3e+00
1.1e+00
6.8e-01
cases:18.70%
controls:7.98%
cases:14.89%
controls:4.58%
cases:6.87%
controls:0.92%
—
—
cases:7.51%
controls:0.80%
cases:11.74%
controls:4.39%
cases:22.29%
controls:12.69%
49
209
213
2411
39
120
223
2500
18
24
244
2596
—
19
21
234
2588
25
111
188
2420
37
273
129
1878
Infectious Disease
44 [38004484]
44 [38004484]
1.7e+00
2.4e+00
-1.0e+50
1.0e+50
—
2.4e+00
1.8e+00
cases:9.16%
controls:1.83%
cases:5.73%
controls:0.53%
cases:0.00%
controls:0.19%
cases:1.91%
controls:0.00%
—
—
cases:5.16%
controls:0.47%
cases:9.64%
controls:1.77%
24
48
238
2572
15
14
247
2606
0
5
262
2615
5
0
257
2620
—
11
12
202
2519
16
38
150
2113
Supine thorax X-ray examination
GD1QA [2001303648]
GD1QA [2001303648]
2.3e+00
2.6e+00
—
1.0e+50
1.9e+00
2.3e+00
1.2e+00
cases:14.12%
controls:1.68%
cases:9.16%
controls:0.76%
—
—
cases:2.29%
controls:0.00%
cases:1.98%
controls:0.31%
cases:7.98%
controls:0.87%
cases:12.05%
controls:4.09%
37
44
225
2576
24
20
238
2600
—
6
0
256
2620
5
8
248
2601
17
22
196
2509
20
88
146
2063
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
9.4e-02
4.4e-01
1.9e+00
4.5e+00
1.9e+00
2.9e-01
2.9e-02
cases:34.73%
controls:32.63%
cases:38.93%
controls:29.08%
cases:30.15%
controls:6.34%
cases:24.81%
controls:0.38%
cases:30.04%
controls:6.06%
cases:35.68%
controls:29.36%
cases:50.60%
controls:49.88%
91
855
171
1765
102
762
160
1858
79
166
183
2454
65
10
197
2610
76
158
177
2451
76
743
137
1788
84
1073
82
1078
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
8.9e-01
1.2e+00
2.1e+00
—
1.9e+00
1.3e+00
8.2e-01
cases:12.60%
controls:5.61%
cases:10.69%
controls:3.40%
cases:3.82%
controls:0.50%
—
—
cases:4.74%
controls:0.73%
cases:11.27%
controls:3.40%
cases:16.27%
controls:7.90%
33
147
229
2473
28
89
234
2531
10
13
252
2607
—
12
19
241
2590
24
86
189
2445
27
170
139
1981
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
9.4e-02
4.5e-01
1.8e+00
4.5e+00
1.9e+00
2.9e-01
3.4e-02
cases:34.73%
controls:32.63%
cases:38.93%
controls:28.97%
cases:29.77%
controls:6.30%
cases:24.81%
controls:0.38%
cases:30.04%
controls:6.06%
cases:35.68%
controls:29.32%
cases:50.60%
controls:49.74%
91
855
171
1765
102
759
160
1861
78
165
184
2455
65
10
197
2610
76
158
177
2451
76
742
137
1789
84
1070
82
1081
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
9.4e-02
4.4e-01
1.8e+00
4.5e+00
1.9e+00
2.9e-01
3.4e-02
cases:34.73%
controls:32.63%
cases:38.93%
controls:29.05%
cases:29.77%
controls:6.30%
cases:24.81%
controls:0.38%
cases:30.04%
controls:6.06%
cases:35.68%
controls:29.32%
cases:50.60%
controls:49.74%
91
855
171
1765
102
761
160
1859
78
165
184
2455
65
10
197
2610
76
158
177
2451
76
742
137
1789
84
1070
82
1081
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
9.4e-02
4.4e-01
1.8e+00
4.5e+00
1.9e+00
2.9e-01
3.4e-02
cases:34.73%
controls:32.63%
cases:38.93%
controls:29.01%
cases:29.77%
controls:6.30%
cases:24.81%
controls:0.38%
cases:30.04%
controls:6.06%
cases:35.68%
controls:29.36%
cases:50.60%
controls:49.74%
91
855
171
1765
102
760
160
1860
78
165
184
2455
65
10
197
2610
76
158
177
2451
76
743
137
1788
84
1070
82
1081
Type 2 diabetes mellitus, with other specified complications
E11.6 [45552387]
E11.6 [45552387]
2.9e+00
2.5e+00
—
—
—
—
2.8e+00
cases:5.34%
controls:0.31%
cases:2.29%
controls:0.19%
—
—
—
—
—
—
—
—
cases:3.61%
controls:0.23%
14
8
248
2612
6
5
256
2615
—
—
—
—
6
5
160
2146
Respiratory and circulatory monitoring
WX700 [2001310817]
WX700 [2001310817]
2.0e+00
1.9e+00
—
—
—
2.9e+00
1.4e+00
cases:9.16%
controls:1.41%
cases:4.58%
controls:0.73%
—
—
—
—
—
—
cases:4.69%
controls:0.28%
cases:8.43%
controls:2.14%
24
37
238
2583
12
19
250
2601
—
—
—
10
7
203
2524
14
46
152
2105
Emergency Medicine
93 [38004510]
93 [38004510]
8.7e-01
1.4e+00
2.5e+00
1.0e+50
2.2e+00
1.1e+00
4.5e-01
cases:25.19%
controls:12.37%
cases:22.52%
controls:6.64%
cases:8.02%
controls:0.69%
cases:13.74%
controls:0.00%
cases:6.72%
controls:0.80%
cases:17.84%
controls:6.44%
cases:30.12%
controls:21.48%
66
324
196
2296
59
174
203
2446
21
18
241
2602
36
0
226
2620
17
21
236
2588
38
163
175
2368
50
462
116
1689
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
4.8e-02
4.3e-01
1.8e+00
4.4e+00
1.8e+00
3.2e-01
6.0e-02
cases:24.43%
controls:23.55%
cases:26.72%
controls:19.16%
cases:20.99%
controls:4.05%
cases:17.56%
controls:0.27%
cases:19.76%
controls:3.87%
cases:24.41%
controls:19.00%
cases:37.95%
controls:36.54%
64
617
198
2003
70
502
192
2118
55
106
207
2514
46
7
216
2613
50
101
203
2508
52
481
161
2050
63
786
103
1365
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
SPAT1144 [2001700245]
2.7e+00
3.2e+00
—
—
1.0e+50
—
2.0e+00
cases:9.16%
controls:0.65%
cases:4.58%
controls:0.19%
—
—
—
—
cases:2.77%
controls:0.00%
—
—
cases:4.82%
controls:0.65%
24
17
238
2603
12
5
250
2615
—
—
7
0
246
2609
—
8
14
158
2137
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
1.0e+00
1.4e+00
1.9e+00
—
1.7e+00
1.2e+00
8.4e-01
cases:24.05%
controls:10.11%
cases:21.37%
controls:6.45%
cases:12.98%
controls:2.29%
—
—
cases:12.25%
controls:2.41%
cases:16.90%
controls:5.97%
cases:27.71%
controls:14.18%
63
265
199
2355
56
169
206
2451
34
60
228
2560
—
31
63
222
2546
36
151
177
2380
46
305
120
1846
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
1.9e-01
5.0e-01
1.7e+00
4.4e+00
1.8e+00
4.1e-01
1.7e-01
cases:23.28%
controls:20.04%
cases:25.19%
controls:16.95%
cases:18.70%
controls:3.97%
cases:16.41%
controls:0.23%
cases:17.39%
controls:3.49%
cases:23.94%
controls:17.27%
cases:36.14%
controls:32.26%
61
525
201
2095
66
444
196
2176
49
104
213
2516
43
6
219
2614
44
91
209
2518
51
437
162
2094
60
694
106
1457
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
1.8e+00
2.0e+00
—
1.0e+50
—
2.8e+00
1.4e+00
cases:9.54%
controls:1.79%
cases:4.96%
controls:0.73%
—
—
cases:1.91%
controls:0.00%
—
—
cases:6.10%
controls:0.40%
cases:9.64%
controls:2.56%
25
47
237
2573
13
19
249
2601
—
5
0
257
2620
—
13
10
200
2521
16
55
150
2096
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
7.8e-01
1.1e+00
1.9e+00
—
1.9e+00
1.2e+00
8.7e-01
cases:17.56%
controls:8.93%
cases:14.89%
controls:5.46%
cases:6.49%
controls:0.99%
—
—
cases:6.32%
controls:1.00%
cases:15.96%
controls:5.61%
cases:27.11%
controls:13.48%
46
234
216
2386
39
143
223
2477
17
26
245
2594
—
16
26
237
2583
34
142
179
2389
45
290
121
1861
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
8.1e-01
1.1e+00
1.9e+00
—
1.8e+00
1.2e+00
8.8e-01
cases:17.56%
controls:8.63%
cases:14.12%
controls:5.34%
cases:6.11%
controls:0.92%
—
—
cases:5.53%
controls:0.96%
cases:15.96%
controls:5.41%
cases:26.51%
controls:12.97%
46
226
216
2394
37
140
225
2480
16
24
246
2596
—
14
25
239
2584
34
137
179
2394
44
279
122
1872
Congestive heart failure
I50.0 [45567179]
I50.0 [45567179]
2.1e+00
2.0e+00
—
—
—
2.1e+00
1.5e+00
cases:6.49%
controls:0.80%
cases:4.58%
controls:0.65%
—
—
—
—
—
—
cases:2.82%
controls:0.36%
cases:6.02%
controls:1.44%
17
21
245
2599
12
17
250
2603
—
—
—
6
9
207
2522
10
31
156
2120
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
1.5e+00
1.7e+00
1.7e+00
—
1.4e+00
1.5e+00
1.3e+00
cases:9.92%
controls:2.48%
cases:9.54%
controls:1.83%
cases:3.82%
controls:0.73%
—
—
cases:2.77%
controls:0.73%
cases:7.51%
controls:1.78%
cases:16.27%
controls:5.07%
26
65
236
2555
25
48
237
2572
10
19
252
2601
—
7
19
246
2590
16
45
197
2486
27
109
139
2042
oxycodone and naloxone; oral
N02AA55 [21604265]
N02AA55 [21604265]
1.8e+00
2.2e+00
—
—
—
2.5e+00
1.2e+00
cases:8.78%
controls:1.60%
cases:8.40%
controls:0.99%
—
—
—
—
—
—
cases:7.98%
controls:0.71%
cases:8.43%
controls:2.70%
23
42
239
2578
22
26
240
2594
—
—
—
17
18
196
2513
14
58
152
2093
Spinalanesthesia
WX320 [2001310799]
WX320 [2001310799]
1.3e+00
2.4e+00
—
1.0e+50
—
2.5e+00
1.5e+00
cases:9.54%
controls:2.86%
cases:9.54%
controls:0.95%
—
—
cases:3.44%
controls:0.00%
—
—
cases:6.10%
controls:0.51%
cases:12.05%
controls:3.02%
25
75
237
2545
25
25
237
2595
—
9
0
253
2620
—
13
13
200
2518
20
65
146
2086
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
9.7e-01
1.2e+00
1.7e+00
—
1.9e+00
1.1e+00
7.8e-01
cases:20.61%
controls:8.93%
cases:15.27%
controls:5.38%
cases:5.73%
controls:1.11%
—
—
cases:6.72%
controls:1.03%
cases:12.68%
controls:4.43%
cases:24.10%
controls:12.74%
54
234
208
2386
40
141
222
2479
15
29
247
2591
—
17
27
236
2582
27
112
186
2419
40
274
126
1877
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
8.2e-01
1.0e+00
1.9e+00
—
1.8e+00
1.2e+00
8.5e-01
cases:17.56%
controls:8.59%
cases:13.74%
controls:5.31%
cases:6.11%
controls:0.92%
—
—
cases:5.53%
controls:0.96%
cases:15.96%
controls:5.45%
cases:25.90%
controls:12.97%
46
225
216
2395
36
139
226
2481
16
24
246
2596
—
14
25
239
2584
34
138
179
2393
43
279
123
1872
Oxygen saturation in Arterial blood
2708-6 [3016502]
2708-6 [3016502]
1.9e+00
2.6e+00
—
—
—
2.0e+00
1.2e+00
cases:6.11%
controls:0.99%
cases:8.02%
controls:0.65%
—
—
—
—
—
—
cases:3.29%
controls:0.47%
cases:7.83%
controls:2.42%
16
26
246
2594
21
17
241
2603
—
—
—
7
12
206
2519
13
52
153
2099
Vitreous haemorrhage
H43.1 [45543053]
H43.1 [45543053]
2.7e+00
2.3e+00
—
—
—
—
2.6e+00
cases:4.96%
controls:0.34%
cases:2.29%
controls:0.23%
—
—
—
—
—
—
—
—
cases:3.61%
controls:0.28%
13
9
249
2611
6
6
256
2614
—
—
—
—
6
6
160
2145
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
7.7e-01
1.1e+00
1.9e+00
—
1.8e+00
1.1e+00
8.9e-01
cases:17.56%
controls:8.97%
cases:14.89%
controls:5.57%
cases:6.11%
controls:0.95%
—
—
cases:5.93%
controls:1.00%
cases:15.96%
controls:5.81%
cases:27.71%
controls:13.58%
46
235
216
2385
39
146
223
2474
16
25
246
2595
—
15
26
238
2583
34
147
179
2384
46
292
120
1859
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
7.6e-01
1.3e+00
2.2e+00
1.0e+50
2.3e+00
9.8e-01
5.9e-01
cases:14.12%
controls:7.14%
cases:12.60%
controls:3.63%
cases:3.44%
controls:0.38%
cases:3.05%
controls:0.00%
cases:4.74%
controls:0.50%
cases:8.45%
controls:3.36%
cases:18.67%
controls:11.25%
37
187
225
2433
33
95
229
2525
9
10
253
2610
8
0
254
2620
12
13
241
2596
18
85
195
2446
31
242
135
1909
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2703-7 [3027801]
1.9e+00
2.5e+00
—
—
—
2.0e+00
1.3e+00
cases:7.25%
controls:1.18%
cases:8.02%
controls:0.73%
—
—
—
—
—
—
cases:3.29%
controls:0.47%
cases:8.43%
controls:2.51%
19
31
243
2589
21
19
241
2601
—
—
—
7
12
206
2519
14
54
152
2097
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2019-8 [3027946]
1.9e+00
2.5e+00
—
—
—
2.0e+00
1.3e+00
cases:7.25%
controls:1.18%
cases:8.02%
controls:0.73%
—
—
—
—
—
—
cases:3.29%
controls:0.47%
cases:8.43%
controls:2.51%
19
31
243
2589
21
19
241
2601
—
—
—
7
12
206
2519
14
54
152
2097
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
6.7e-01
1.1e+00
1.7e+00
—
2.0e+00
1.2e+00
8.4e-01
cases:14.89%
controls:8.21%
cases:13.36%
controls:4.85%
cases:4.58%
controls:0.84%
—
—
cases:6.32%
controls:0.92%
cases:15.02%
controls:4.86%
cases:24.70%
controls:12.37%
39
215
223
2405
35
127
227
2493
12
22
250
2598
—
16
24
237
2585
32
123
181
2408
41
266
125
1885
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
7.0e-01
1.1e+00
1.7e+00
—
1.9e+00
1.2e+00
8.5e-01
cases:15.27%
controls:8.21%
cases:13.36%
controls:4.85%
cases:4.58%
controls:0.84%
—
—
cases:6.32%
controls:0.96%
cases:15.02%
controls:4.86%
cases:24.70%
controls:12.27%
40
215
222
2405
35
127
227
2493
12
22
250
2598
—
16
25
237
2584
32
123
181
2408
41
264
125
1887
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
7.0e-01
1.1e+00
1.7e+00
—
2.0e+00
1.2e+00
8.5e-01
cases:15.27%
controls:8.24%
cases:13.36%
controls:4.81%
cases:4.58%
controls:0.88%
—
—
cases:6.32%
controls:0.92%
cases:15.02%
controls:4.86%
cases:24.70%
controls:12.27%
40
216
222
2404
35
126
227
2494
12
23
250
2597
—
16
24
237
2585
32
123
181
2408
41
264
125
1887
Base excess in Arterial blood by calculation
1925-7 [3003396]
1925-7 [3003396]
1.9e+00
2.5e+00
—
—
—
2.0e+00
1.3e+00
cases:6.87%
controls:1.15%
cases:8.02%
controls:0.73%
—
—
—
—
—
—
cases:3.29%
controls:0.47%
cases:9.04%
controls:2.74%
18
30
244
2590
21
19
241
2601
—
—
—
7
12
206
2519
15
59
151
2092
pH of Arterial blood
2744-1 [3019977]
2744-1 [3019977]
1.9e+00
2.5e+00
—
—
—
2.0e+00
1.2e+00
cases:6.87%
controls:1.15%
cases:8.02%
controls:0.69%
—
—
—
—
—
—
cases:3.29%
controls:0.47%
cases:8.43%
controls:2.70%
18
30
244
2590
21
18
241
2602
—
—
—
7
12
206
2519
14
58
152
2093
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
54067-4 [3051552]
2.2e+00
2.9e+00
1.0e+50
—
—
2.4e+00
1.4e+00
cases:7.25%
controls:0.84%
cases:6.87%
controls:0.42%
cases:3.44%
controls:0.00%
—
—
—
—
cases:3.76%
controls:0.36%
cases:4.82%
controls:1.26%
19
22
243
2598
18
11
244
2609
9
0
253
2620
—
—
8
9
205
2522
8
27
158
2124
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
2.9e-01
4.2e-01
1.7e+00
4.2e+00
1.6e+00
2.3e-01
1.8e-01
cases:26.34%
controls:21.11%
cases:25.57%
controls:18.44%
cases:17.94%
controls:4.01%
cases:14.89%
controls:0.27%
cases:17.39%
controls:3.95%
cases:23.94%
controls:20.03%
cases:37.95%
controls:33.89%
69
553
193
2067
67
483
195
2137
47
105
215
2515
39
7
223
2613
44
103
209
2506
51
507
162
2024
63
729
103
1422
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
8.9e-01
1.2e+00
1.6e+00
—
1.9e+00
9.8e-01
8.7e-01
cases:11.45%
controls:5.04%
cases:9.16%
controls:3.09%
cases:3.44%
controls:0.69%
—
—
cases:3.56%
controls:0.54%
cases:7.98%
controls:3.16%
cases:16.87%
controls:7.86%
30
132
232
2488
24
81
238
2539
9
18
253
2602
—
9
14
244
2595
17
80
196
2451
28
169
138
1982
Atrial fibrillation and flutter
I48 [45596206]
I48 [45596206]
9.7e-01
1.4e+00
2.4e+00
1.0e+50
1.6e+00
1.1e+00
7.8e-01
cases:16.41%
controls:6.91%
cases:12.98%
controls:3.70%
cases:8.02%
controls:0.80%
cases:4.58%
controls:0.00%
cases:4.74%
controls:0.96%
cases:8.92%
controls:3.20%
cases:15.06%
controls:7.53%
43
181
219
2439
34
97
228
2523
21
21
241
2599
12
0
250
2620
12
25
241
2584
19
81
194
2450
25
162
141
1989
Hand Surgery
40 [38004480]
40 [38004480]
8.1e-01
1.5e+00
—
1.0e+50
2.3e+00
1.9e+00
1.7e+00
cases:4.20%
controls:1.91%
cases:3.44%
controls:0.80%
—
—
cases:4.58%
controls:0.00%
cases:1.98%
controls:0.19%
cases:4.23%
controls:0.67%
cases:10.24%
controls:2.00%
11
50
251
2570
9
21
253
2599
—
12
0
250
2620
5
5
248
2604
9
17
204
2514
17
43
149
2108
Handing over of treatment supplies
SPAT1262 [2001700363]
SPAT1262 [2001700363]
1.4e+00
1.5e+00
1.3e+00
—
2.0e+00
1.4e+00
1.2e+00
cases:13.36%
controls:3.82%
cases:10.31%
controls:2.52%
cases:1.91%
controls:0.53%
—
—
cases:3.95%
controls:0.57%
cases:8.92%
controls:2.45%
cases:16.87%
controls:5.53%
35
100
227
2520
27
66
235
2554
5
14
257
2606
—
10
15
243
2594
19
62
194
2469
28
119
138
2032
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
8.3e-01
1.4e+00
2.2e+00
—
2.0e+00
1.0e+00
6.1e-01
cases:18.70%
controls:9.08%
cases:17.94%
controls:5.19%
cases:8.02%
controls:0.95%
—
—
cases:6.72%
controls:1.00%
cases:13.15%
controls:5.18%
cases:23.49%
controls:14.27%
49
238
213
2382
47
136
215
2484
21
25
241
2595
—
17
26
236
2583
28
131
185
2400
39
307
127
1844
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
1.8e+00
2.5e+00
—
—
—
1.7e+00
1.3e+00
cases:5.73%
controls:0.95%
cases:6.11%
controls:0.53%
—
—
—
—
—
—
cases:3.29%
controls:0.59%
cases:10.24%
controls:2.98%
15
25
247
2595
16
14
246
2606
—
—
—
7
15
206
2516
17
64
149
2087
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
6.7e-01
1.1e+00
1.7e+00
—
1.9e+00
1.2e+00
7.8e-01
cases:15.27%
controls:8.47%
cases:13.74%
controls:5.00%
cases:4.58%
controls:0.88%
—
—
cases:6.32%
controls:0.96%
cases:15.02%
controls:5.18%
cases:24.10%
controls:12.74%
40
222
222
2398
36
131
226
2489
12
23
250
2597
—
16
25
237
2584
32
131
181
2400
40
274
126
1877
codeine and paracetamol
N02AJ06 [1123647]
N02AJ06 [1123647]
1.1e+00
1.5e+00
1.4e+00
—
1.6e+00
8.7e-01
7.7e-01
cases:28.24%
controls:11.95%
cases:17.94%
controls:4.66%
cases:4.96%
controls:1.26%
—
—
cases:4.74%
controls:0.96%
cases:12.21%
controls:5.49%
cases:24.70%
controls:13.16%
74
313
188
2307
47
122
215
2498
13
33
249
2587
—
12
25
241
2584
26
139
187
2392
41
283
125
1868
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
1.5e+00
1.9e+00
2.3e+00
—
2.5e+00
1.4e+00
1.3e+00
cases:9.92%
controls:2.44%
cases:7.63%
controls:1.18%
cases:1.91%
controls:0.19%
—
—
cases:2.77%
controls:0.23%
cases:4.23%
controls:1.03%
cases:10.84%
controls:3.11%
26
64
236
2556
20
31
242
2589
5
5
257
2615
—
7
6
246
2603
9
26
204
2505
18
67
148
2084
Other chronic renal failure
N18.8 [45534123]
N18.8 [45534123]
2.5e+00
2.6e+00
—
—
—
1.9e+00
2.1e+00
cases:6.11%
controls:0.53%
cases:3.05%
controls:0.23%
—
—
—
—
—
—
cases:2.35%
controls:0.36%
cases:6.02%
controls:0.74%
16
14
246
2606
8
6
254
2614
—
—
—
5
9
208
2522
10
16
156
2135
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
1.6e+00
2.3e+00
—
—
—
1.9e+00
1.5e+00
cases:9.92%
controls:2.25%
cases:9.16%
controls:0.95%
—
—
—
—
—
—
cases:7.98%
controls:1.34%
cases:14.46%
controls:3.67%
26
59
236
2561
24
25
238
2595
—
—
—
17
34
196
2497
24
79
142
2072
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
1.7e+00
2.3e+00
—
—
—
1.7e+00
1.5e+00
cases:9.92%
controls:2.02%
cases:8.78%
controls:0.92%
—
—
—
—
—
—
cases:7.04%
controls:1.30%
cases:13.86%
controls:3.58%
26
53
236
2567
23
24
239
2596
—
—
—
15
33
198
2498
23
77
143
2074
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
W01 [45756243]
1.2e+00
1.7e+00
—
1.0e+50
2.7e+00
1.5e+00
5.7e-01
cases:13.74%
controls:4.54%
cases:7.25%
controls:1.37%
—
—
cases:2.67%
controls:0.00%
cases:2.77%
controls:0.19%
cases:6.10%
controls:1.38%
cases:11.45%
controls:6.79%
36
119
226
2501
19
36
243
2584
—
7
0
255
2620
7
5
246
2604
13
35
200
2496
19
146
147
2005
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
1.2e+00
1.7e+00
—
1.0e+50
—
2.8e+00
1.5e+00
cases:14.89%
controls:4.89%
cases:6.49%
controls:1.30%
—
—
cases:2.29%
controls:0.00%
—
—
cases:9.39%
controls:0.63%
cases:13.86%
controls:3.53%
39
128
223
2492
17
34
245
2586
—
6
0
256
2620
—
20
16
193
2515
23
76
143
2075
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
2075-0 [3014576]
1.7e+00
2.3e+00
—
—
—
1.8e+00
1.3e+00
cases:5.73%
controls:1.07%
cases:7.63%
controls:0.80%
—
—
—
—
—
—
cases:4.23%
controls:0.75%
cases:10.24%
controls:3.07%
15
28
247
2592
20
21
242
2599
—
—
—
9
19
204
2512
17
66
149
2085
Acute subendocardial infarction unspecified coronary artery status
I21.49 [2000502437]
I21.49 [2000502437]
1.6e+00
2.5e+00
—
—
—
—
2.9e+00
cases:3.05%
controls:0.61%
cases:2.29%
controls:0.19%
—
—
—
—
—
—
—
—
cases:6.63%
controls:0.37%
8
16
254
2604
6
5
256
2615
—
—
—
—
11
8
155
2143
Photocoagulation of retina
CKC12 [2001301394]
CKC12 [2001301394]
2.3e+00
2.5e+00
—
—
—
2.3e+00
1.8e+00
cases:6.11%
controls:0.65%
cases:3.44%
controls:0.31%
—
—
—
—
—
—
cases:2.35%
controls:0.24%
cases:3.01%
controls:0.51%
16
17
246
2603
9
8
253
2612
—
—
—
5
6
208
2525
5
11
161
2140
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
6.7e-01
1.1e+00
1.5e+00
—
1.8e+00
1.1e+00
7.6e-01
cases:14.89%
controls:8.21%
cases:13.74%
controls:5.00%
cases:4.20%
controls:0.95%
—
—
cases:5.53%
controls:0.92%
cases:15.02%
controls:5.33%
cases:23.49%
controls:12.51%
39
215
223
2405
36
131
226
2489
11
25
251
2595
—
14
24
239
2585
32
135
181
2396
39
269
127
1882
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
1.1e+00
1.5e+00
—
—
—
2.6e+00
1.8e+00
cases:10.31%
controls:3.59%
cases:4.20%
controls:0.99%
—
—
—
—
—
—
cases:3.76%
controls:0.28%
cases:11.45%
controls:2.19%
27
94
235
2526
11
26
251
2594
—
—
—
8
7
205
2524
19
47
147
2104
insulin detemir; parenteral
A10AE05 [21600740]
A10AE05 [21600740]
1.9e+00
1.7e+00
2.1e+00
—
—
1.3e+00
1.1e+00
cases:10.31%
controls:1.72%
cases:7.63%
controls:1.53%
cases:2.67%
controls:0.34%
—
—
—
—
cases:5.63%
controls:1.58%
cases:6.02%
controls:2.00%
27
45
235
2575
20
40
242
2580
7
9
255
2611
—
—
12
40
201
2491
10
43
156
2108
insulin (beef); parenteral
A10AD02 [21600730]
A10AD02 [21600730]
1.9e+00
1.8e+00
1.4e+00
—
1.4e+00
1.6e+00
1.6e+00
cases:20.23%
controls:3.70%
cases:18.32%
controls:3.47%
cases:3.44%
controls:0.84%
—
—
cases:3.16%
controls:0.80%
cases:15.96%
controls:3.67%
cases:19.88%
controls:4.74%
53
97
209
2523
48
91
214
2529
9
22
253
2598
—
8
21
245
2588
34
93
179
2438
33
102
133
2049
insulin glargine; parenteral
A10AE04 [21600739]
A10AE04 [21600739]
1.9e+00
1.8e+00
1.4e+00
—
1.4e+00
1.6e+00
1.6e+00
cases:20.23%
controls:3.70%
cases:18.32%
controls:3.47%
cases:3.44%
controls:0.84%
—
—
cases:3.16%
controls:0.80%
cases:15.96%
controls:3.67%
cases:19.88%
controls:4.74%
53
97
209
2523
48
91
214
2529
9
22
253
2598
—
8
21
245
2588
34
93
179
2438
33
102
133
2049
Cellulitis of finger and toe
L03.0 [45557691]
L03.0 [45557691]
2.4e+00
2.2e+00
—
—
—
2.3e+00
1.4e+00
cases:4.20%
controls:0.38%
cases:2.29%
controls:0.27%
—
—
—
—
—
—
cases:2.35%
controls:0.24%
cases:3.01%
controls:0.79%
11
10
251
2610
6
7
256
2613
—
—
—
5
6
208
2525
5
17
161
2134
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
1.4e+00
2.1e+00
—
—
—
2.2e+00
1.2e+00
cases:9.16%
controls:2.40%
cases:4.58%
controls:0.57%
—
—
—
—
—
—
cases:6.57%
controls:0.75%
cases:9.64%
controls:3.25%
24
63
238
2557
12
15
250
2605
—
—
—
14
19
199
2512
16
70
150
2081
X-ray examination of the lungs in one projection
GD1PA [2001303645]
GD1PA [2001303645]
2.4e+00
2.6e+00
—
—
—
—
1.9e+00
cases:8.02%
controls:0.76%
cases:6.49%
controls:0.53%
—
—
—
—
—
—
—
—
cases:9.04%
controls:1.44%
21
20
241
2600
17
14
245
2606
—
—
—
—
15
31
151
2120
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
34487-9 [3044938]
1.8e+00
2.2e+00
—
1.0e+50
—
1.5e+00
1.3e+00
cases:8.02%
controls:1.41%
cases:6.87%
controls:0.80%
—
—
cases:1.91%
controls:0.00%
—
—
cases:4.23%
controls:0.95%
cases:13.25%
controls:4.04%
21
37
241
2583
18
21
244
2599
—
5
0
257
2620
—
9
24
204
2507
22
87
144
2064
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
3.4e-01
1.0e+00
2.3e+00
—
2.6e+00
8.4e-01
3.8e-01
cases:32.06%
controls:25.15%
cases:36.64%
controls:17.10%
cases:28.24%
controls:3.74%
—
—
cases:29.25%
controls:2.87%
cases:30.52%
controls:15.92%
cases:45.78%
controls:36.59%
84
659
178
1961
96
448
166
2172
74
98
188
2522
—
74
75
179
2534
65
403
148
2128
76
787
90
1364
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
9.4e-02
2.9e-01
1.3e+00
4.0e+00
1.5e+00
1.8e-01
-2.2e-02
cases:37.79%
controls:35.61%
cases:41.22%
controls:34.39%
cases:33.59%
controls:11.79%
cases:27.86%
controls:0.73%
cases:34.78%
controls:10.69%
cases:40.38%
controls:36.03%
cases:53.61%
controls:54.16%
99
933
163
1687
108
901
154
1719
88
309
174
2311
73
19
189
2601
88
279
165
2330
86
912
127
1619
89
1165
77
986
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
5.8e-01
1.2e+00
2.2e+00
—
1.8e+00
1.0e+00
4.8e-01
cases:20.61%
controls:12.71%
cases:19.08%
controls:6.83%
cases:9.16%
controls:1.15%
—
—
cases:7.51%
controls:1.26%
cases:16.43%
controls:6.68%
cases:28.31%
controls:19.67%
54
333
208
2287
50
179
212
2441
24
30
238
2590
—
19
33
234
2576
35
169
178
2362
47
423
119
1728
Left side
ZXA05 [2001311347]
ZXA05 [2001311347]
1.0e+00
2.2e+00
—
1.0e+50
—
2.0e+00
1.5e+00
cases:10.69%
controls:4.05%
cases:7.25%
controls:0.88%
—
—
cases:1.91%
controls:0.00%
—
—
cases:5.16%
controls:0.75%
cases:12.05%
controls:2.88%
28
106
234
2514
19
23
243
2597
—
5
0
257
2620
—
11
19
202
2512
20
62
146
2089
Musculoskeletal sympt/complt other
L29 [2002000648]
L29 [2002000648]
1.3e+00
2.5e+00
—
—
—
2.5e+00
1.8e+00
cases:2.67%
controls:0.76%
cases:3.44%
controls:0.31%
—
—
—
—
—
—
cases:2.82%
controls:0.24%
cases:5.42%
controls:0.98%
7
20
255
2600
9
8
253
2612
—
—
—
6
6
207
2525
9
21
157
2130
Gas panel - Venous blood
24339-4 [3000991]
24339-4 [3000991]
1.5e+00
2.2e+00
—
—
—
1.6e+00
1.4e+00
cases:4.58%
controls:1.07%
cases:5.34%
controls:0.61%
—
—
—
—
—
—
cases:3.76%
controls:0.79%
cases:7.23%
controls:1.91%
12
28
250
2592
14
16
248
2604
—
—
—
8
20
205
2511
12
41
154
2110
Intravenous administration of medicine
SPAT1255 [2001700356]
SPAT1255 [2001700356]
2.5e+00
2.0e+00
—
—
—
—
2.1e+00
cases:6.49%
controls:0.57%
cases:2.29%
controls:0.31%
—
—
—
—
—
—
—
—
cases:6.02%
controls:0.74%
17
15
245
2605
6
8
256
2612
—
—
—
—
10
16
156
2135
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
OMOP4821991 [45756751]
1.5e+00
2.7e+00
—
—
—
—
2.4e+00
cases:3.44%
controls:0.80%
cases:2.67%
controls:0.19%
—
—
—
—
—
—
—
—
cases:8.43%
controls:0.79%
9
21
253
2599
7
5
255
2615
—
—
—
—
14
17
152
2134
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
SPAT1230 [2001700331]
1.6e+00
2.2e+00
—
—
—
1.5e+00
1.3e+00
cases:9.16%
controls:1.91%
cases:8.02%
controls:0.99%
—
—
—
—
—
—
cases:4.69%
controls:1.11%
cases:9.64%
controls:2.84%
24
50
238
2570
21
26
241
2594
—
—
—
10
28
203
2503
16
61
150
2090
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
6.7e-01
1.1e+00
1.9e+00
—
2.0e+00
8.7e-01
4.8e-01
cases:31.68%
controls:19.16%
cases:23.28%
controls:9.27%
cases:8.78%
controls:1.41%
—
—
cases:10.28%
controls:1.46%
cases:19.72%
controls:9.36%
cases:34.34%
controls:24.50%
83
502
179
2118
61
243
201
2377
23
37
239
2583
—
26
38
227
2571
42
237
171
2294
57
527
109
1624
Sampling
SPAT1263 [2001700364]
SPAT1263 [2001700364]
1.1e+00
1.3e+00
1.9e+00
—
9.6e-01
1.3e+00
9.6e-01
cases:20.99%
controls:8.13%
cases:11.45%
controls:3.47%
cases:4.58%
controls:0.73%
—
—
cases:2.37%
controls:0.92%
cases:12.21%
controls:3.56%
cases:21.08%
controls:9.30%
55
213
207
2407
30
91
232
2529
12
19
250
2601
—
6
24
247
2585
26
90
187
2441
35
200
131
1951
insulin degludec; parenteral
A10AE06 [43534747]
A10AE06 [43534747]
2.2e+00
2.2e+00
—
—
—
2.1e+00
1.1e+00
cases:3.05%
controls:0.34%
cases:3.82%
controls:0.42%
—
—
—
—
—
—
cases:4.23%
controls:0.55%
cases:3.01%
controls:0.98%
8
9
254
2611
10
11
252
2609
—
—
—
9
14
204
2517
5
21
161
2130
Psychiatry
26 [38004469]
26 [38004469]
9.4e-01
1.2e+00
1.5e+00
—
1.5e+00
1.3e+00
1.5e+00
cases:10.31%
controls:4.31%
cases:6.49%
controls:1.98%
cases:3.05%
controls:0.73%
—
—
cases:3.56%
controls:0.80%
cases:5.63%
controls:1.54%
cases:14.46%
controls:3.72%
27
113
235
2507
17
52
245
2568
8
19
254
2601
—
9
21
244
2588
12
39
201
2492
24
80
142
2071
Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]
SPAT1156 [2001700257]
1.6e+00
1.9e+00
—
—
—
1.6e+00
1.4e+00
cases:7.63%
controls:1.72%
cases:3.82%
controls:0.57%
—
—
—
—
—
—
cases:3.76%
controls:0.79%
cases:7.23%
controls:1.86%
20
45
242
2575
10
15
252
2605
—
—
—
8
20
205
2511
12
40
154
2111
Application of soft bandage
SPAT1211 [2001700312]
SPAT1211 [2001700312]
1.5e+00
2.7e+00
—
—
—
2.3e+00
1.6e+00
cases:4.58%
controls:1.07%
cases:3.82%
controls:0.27%
—
—
—
—
—
—
cases:3.29%
controls:0.36%
cases:4.22%
controls:0.88%
12
28
250
2592
10
7
252
2613
—
—
—
7
9
206
2522
7
19
159
2132
clopidogrel; oral
B01AC04 [21600989]
B01AC04 [21600989]
1.6e+00
1.6e+00
1.3e+00
—
1.4e+00
1.5e+00
1.7e+00
cases:16.03%
controls:3.70%
cases:11.07%
controls:2.37%
cases:2.29%
controls:0.61%
—
—
cases:2.37%
controls:0.61%
cases:9.86%
controls:2.37%
cases:17.47%
controls:3.86%
42
97
220
2523
29
62
233
2558
6
16
256
2604
—
6
16
247
2593
21
60
192
2471
29
83
137
2068
Cardiology
6 [38004451]
6 [38004451]
1.1e+00
1.2e+00
2.0e+00
—
1.4e+00
1.1e+00
1.1e+00
cases:27.10%
controls:11.49%
cases:15.65%
controls:5.46%
cases:5.73%
controls:0.80%
—
—
cases:2.37%
controls:0.61%
cases:11.74%
controls:4.35%
cases:29.52%
controls:12.37%
71
301
191
2319
41
143
221
2477
15
21
247
2599
—
6
16
247
2593
25
110
188
2421
49
266
117
1885
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
5.5e-01
9.3e-01
1.6e+00
—
1.8e+00
8.2e-01
6.8e-01
cases:25.57%
controls:16.56%
cases:22.90%
controls:10.46%
cases:8.78%
controls:1.91%
—
—
cases:10.28%
controls:1.88%
cases:18.78%
controls:9.25%
cases:37.95%
controls:23.57%
67
434
195
2186
60
274
202
2346
23
50
239
2570
—
26
49
227
2560
40
234
173
2297
63
507
103
1644
Puncture of vitreous body with injection of medication
CKD05 [2001301407]
CKD05 [2001301407]
1.2e+00
2.1e+00
—
—
—
2.4e+00
1.8e+00
cases:3.05%
controls:0.92%
cases:4.58%
controls:0.57%
—
—
—
—
—
—
cases:4.69%
controls:0.43%
cases:5.42%
controls:0.93%
8
24
254
2596
12
15
250
2605
—
—
—
10
11
203
2520
9
20
157
2131
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
19230-2 [3014218]
2.0e+00
2.6e+00
—
—
—
—
1.6e+00
cases:3.05%
controls:0.42%
cases:3.44%
controls:0.27%
—
—
—
—
—
—
—
—
cases:6.02%
controls:1.26%
8
11
254
2609
9
7
253
2613
—
—
—
—
10
27
156
2124
Type 2 diabetes mellitus, with renal complications
E11.2 [45605400]
E11.2 [45605400]
2.3e+00
—
—
—
—
2.0e+00
1.8e+00
cases:4.20%
controls:0.42%
—
—
—
—
—
—
—
—
cases:2.82%
controls:0.40%
cases:4.82%
controls:0.79%
11
11
251
2609
—
—
—
—
6
10
207
2521
8
17
158
2134
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
2731-8 [3000067]
1.5e+00
1.9e+00
—
—
—
1.6e+00
1.3e+00
cases:5.73%
controls:1.37%
cases:5.34%
controls:0.88%
—
—
—
—
—
—
cases:4.69%
controls:1.03%
cases:8.43%
controls:2.46%
15
36
247
2584
14
23
248
2597
—
—
—
10
26
203
2505
14
53
152
2098
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
9.0e-01
1.2e+00
2.7e+00
—
—
1.4e+00
6.1e-01
cases:7.63%
controls:3.24%
cases:5.34%
controls:1.76%
cases:3.44%
controls:0.23%
—
—
—
—
cases:5.63%
controls:1.50%
cases:9.64%
controls:5.49%
20
85
242
2535
14
46
248
2574
9
6
253
2614
—
—
12
38
201
2493
16
118
150
2033
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
30313-1 [3002173]
1.6e+00
2.5e+00
—
—
—
2.0e+00
1.1e+00
cases:4.58%
controls:0.95%
cases:6.87%
controls:0.57%
—
—
—
—
—
—
cases:2.82%
controls:0.40%
cases:6.02%
controls:2.09%
12
25
250
2595
18
15
244
2605
—
—
—
6
10
207
2521
10
45
156
2106
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]
SPAT1220 [2001700321]
1.6e+00
2.3e+00
—
—
—
—
2.0e+00
cases:3.05%
controls:0.61%
cases:2.29%
controls:0.23%
—
—
—
—
—
—
—
—
cases:3.61%
controls:0.51%
8
16
254
2604
6
6
256
2614
—
—
—
—
6
11
160
2140
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
1.9e+00
2.4e+00
—
—
—
1.6e+00
1.5e+00
cases:5.34%
controls:0.88%
cases:5.34%
controls:0.50%
—
—
—
—
—
—
cases:2.82%
controls:0.59%
cases:10.84%
controls:2.65%
14
23
248
2597
14
13
248
2607
—
—
—
6
15
207
2516
18
57
148
2094
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
1.0e+00
1.7e+00
3.0e+00
—
—
1.1e+00
9.7e-01
cases:11.07%
controls:4.35%
cases:8.02%
controls:1.56%
cases:4.58%
controls:0.23%
—
—
—
—
cases:3.76%
controls:1.22%
cases:9.04%
controls:3.63%
29
114
233
2506
21
41
241
2579
12
6
250
2614
—
—
8
31
205
2500
15
78
151
2073
Hemodialysis
TK800 [2001305768]
TK800 [2001305768]
2.7e+00
—
—
1.0e+50
—
—
3.1e+00
cases:4.20%
controls:0.31%
—
—
—
—
cases:1.91%
controls:0.00%
—
—
—
—
cases:4.82%
controls:0.23%
11
8
251
2612
—
—
5
0
257
2620
—
—
8
5
158
2146
spironolactone; oral
C03DA01 [21601534]
C03DA01 [21601534]
1.6e+00
1.6e+00
1.2e+00
—
—
1.2e+00
1.1e+00
cases:9.16%
controls:1.91%
cases:9.16%
controls:1.91%
cases:1.91%
controls:0.61%
—
—
—
—
cases:6.10%
controls:1.98%
cases:9.04%
controls:3.16%
24
50
238
2570
24
50
238
2570
5
16
257
2604
—
—
13
50
200
2481
15
68
151
2083
Cathetrisation of artery
TPH07 [2001309747]
TPH07 [2001309747]
1.8e+00
2.3e+00
—
—
—
—
1.5e+00
cases:5.73%
controls:1.03%
cases:4.20%
controls:0.46%
—
—
—
—
—
—
—
—
cases:6.63%
controls:1.49%
15
27
247
2593
11
12
251
2608
—
—
—
—
11
32
155
2119
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
9.2e-01
1.0e+00
—
—
2.5e+00
5.5e-01
1.0e+00
cases:11.45%
controls:4.92%
cases:6.11%
controls:2.29%
—
—
—
—
cases:3.16%
controls:0.27%
cases:4.69%
controls:2.77%
cases:18.67%
controls:7.48%
30
129
232
2491
16
60
246
2560
—
—
8
7
245
2602
10
70
203
2461
31
161
135
1990
Insertion of central venous catheter through subclavian or brachiocephalic vein
TPH20 [2001309601]
TPH20 [2001309601]
2.5e+00
—
—
—
—
—
2.9e+00
cases:2.29%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:4.22%
controls:0.23%
6
5
256
2615
—
—
—
—
—
7
5
159
2146
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
33762-6 [3029187]
1.2e+00
1.1e+00
2.1e+00
—
1.5e+00
6.5e-01
1.0e+00
cases:13.74%
controls:4.73%
cases:8.78%
controls:3.05%
cases:4.58%
controls:0.57%
—
—
cases:1.98%
controls:0.46%
cases:5.16%
controls:2.77%
cases:20.48%
controls:8.69%
36
124
226
2496
23
80
239
2540
12
15
250
2605
—
5
12
248
2597
11
70
202
2461
34
187
132
1964
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
SPAT1223 [2001700324]
8.8e-01
1.5e+00
—
—
—
1.8e+00
1.2e+00
cases:9.92%
controls:4.35%
cases:6.87%
controls:1.60%
—
—
—
—
—
—
cases:7.98%
controls:1.42%
cases:14.46%
controls:4.88%
26
114
236
2506
18
42
244
2578
—
—
—
17
36
196
2495
24
105
142
2046
Bacteria identified in Urine by Culture
630-4 [3026008]
630-4 [3026008]
7.7e-01
1.5e+00
2.7e+00
—
1.9e+00
1.1e+00
7.1e-01
cases:9.16%
controls:4.47%
cases:10.69%
controls:2.52%
cases:4.58%
controls:0.31%
—
—
cases:2.37%
controls:0.34%
cases:7.51%
controls:2.65%
cases:16.87%
controls:9.07%
24
117
238
2503
28
66
234
2554
12
8
250
2612
—
6
9
247
2600
16
67
197
2464
28
195
138
1956
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
J01CR02 [21602863]
8.3e-01
1.5e+00
—
—
1.9e+00
1.1e+00
6.2e-01
cases:14.50%
controls:6.91%
cases:8.40%
controls:2.02%
—
—
—
—
cases:2.77%
controls:0.42%
cases:6.57%
controls:2.29%
cases:11.45%
controls:6.51%
38
181
224
2439
22
53
240
2567
—
—
7
11
246
2598
14
58
199
2473
19
140
147
2011
Counselling and guidance which enhance independent living
R2130 [2001310196]
R2130 [2001310196]
1.2e+00
2.8e+00
—
—
—
2.5e+00
—
cases:2.67%
controls:0.84%
cases:3.05%
controls:0.19%
—
—
—
—
—
—
cases:3.29%
controls:0.28%
—
—
7
22
255
2598
8
5
254
2615
—
—
—
7
7
206
2524
—
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-1.9e-01
-3.5e-01
—
—
—
2.3e+00
3.0e+00
cases:20.61%
controls:23.82%
cases:5.34%
controls:7.40%
—
—
—
—
—
—
cases:3.76%
controls:0.40%
cases:15.06%
controls:0.88%
54
624
208
1996
14
194
248
2426
—
—
—
8
10
205
2521
25
19
141
2132
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
1.3e+00
2.2e+00
—
—
—
1.6e+00
1.7e+00
cases:8.78%
controls:2.48%
cases:8.78%
controls:1.03%
—
—
—
—
—
—
cases:3.29%
controls:0.67%
cases:16.27%
controls:3.49%
23
65
239
2555
23
27
239
2593
—
—
—
7
17
206
2514
27
75
139
2076
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
19232-8 [3007628]
1.6e+00
1.6e+00
—
—
—
—
2.0e+00
cases:3.82%
controls:0.80%
cases:3.05%
controls:0.61%
—
—
—
—
—
—
—
—
cases:6.63%
controls:0.98%
10
21
252
2599
8
16
254
2604
—
—
—
—
11
21
155
2130
Skin infection other
S76 [2002001040]
S76 [2002001040]
2.6e+00
—
—
—
—
—
2.5e+00
cases:4.96%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:0.60%
13
10
249
2610
—
—
—
—
—
12
13
154
2138
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
6.0e-01
1.2e+00
2.5e+00
—
—
1.5e+00
5.6e-01
cases:6.49%
controls:3.66%
cases:5.73%
controls:1.79%
cases:2.29%
controls:0.19%
—
—
—
—
cases:6.57%
controls:1.62%
cases:9.04%
controls:5.39%
17
96
245
2524
15
47
247
2573
6
5
256
2615
—
—
14
41
199
2490
15
116
151
2035
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
5.6e-01
1.1e+00
1.5e+00
—
1.5e+00
1.0e+00
6.1e-01
cases:16.41%
controls:10.08%
cases:16.03%
controls:6.26%
cases:7.25%
controls:1.64%
—
—
cases:5.93%
controls:1.34%
cases:16.43%
controls:6.60%
cases:24.70%
controls:15.06%
43
264
219
2356
42
164
220
2456
19
43
243
2577
—
15
35
238
2574
35
167
178
2364
41
324
125
1827
Exposure to other specified factors
X58 [45756411]
X58 [45756411]
1.1e+00
2.5e+00
—
1.0e+50
—
2.6e+00
—
cases:4.58%
controls:1.53%
cases:4.58%
controls:0.38%
—
—
cases:6.87%
controls:0.00%
—
—
cases:4.69%
controls:0.36%
—
—
12
40
250
2580
12
10
250
2610
—
18
0
244
2620
—
10
9
203
2522
—
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
J44.8 [45586673]
1.1e+00
1.4e+00
2.7e+00
1.0e+50
—
9.2e-01
6.6e-01
cases:5.73%
controls:2.02%
cases:4.20%
controls:1.07%
cases:2.67%
controls:0.19%
cases:1.91%
controls:0.00%
—
—
cases:2.82%
controls:1.15%
cases:5.42%
controls:2.88%
15
53
247
2567
11
28
251
2592
7
5
255
2615
5
0
257
2620
—
6
29
207
2502
9
62
157
2089
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
8.1e-02
3.8e-01
9.1e-01
3.4e+00
7.3e-01
2.6e-01
-4.6e-03
cases:61.45%
controls:59.50%
cases:61.83%
controls:52.60%
cases:39.31%
controls:20.61%
cases:28.63%
controls:1.26%
cases:36.76%
controls:21.89%
cases:61.50%
controls:55.12%
cases:71.69%
controls:71.78%
161
1559
101
1061
162
1378
100
1242
103
540
159
2080
75
33
187
2587
93
571
160
2038
131
1395
82
1136
119
1544
47
607
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
2524-7 [3014111]
1.5e+00
2.2e+00
—
—
-1.0e+50
1.7e+00
1.4e+00
cases:3.82%
controls:0.88%
cases:5.73%
controls:0.65%
—
—
—
—
cases:0.00%
controls:0.19%
cases:2.82%
controls:0.51%
cases:7.23%
controls:1.95%
10
23
252
2597
15
17
247
2603
—
—
0
5
253
2604
6
13
207
2518
12
42
154
2109
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
7.2e-01
9.4e-01
1.3e+00
—
1.2e+00
8.4e-01
4.6e-01
cases:48.09%
controls:31.11%
cases:37.02%
controls:18.63%
cases:10.69%
controls:3.09%
—
—
cases:11.46%
controls:3.64%
cases:32.86%
controls:17.50%
cases:51.81%
controls:40.45%
126
815
136
1805
97
488
165
2132
28
81
234
2539
—
29
95
224
2514
70
443
143
2088
86
870
80
1281
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
2020-6 [3023024]
1.4e+00
1.8e+00
—
—
—
1.9e+00
1.3e+00
cases:3.82%
controls:0.99%
cases:2.67%
controls:0.46%
—
—
—
—
—
—
cases:3.76%
controls:0.59%
cases:6.02%
controls:1.67%
10
26
252
2594
7
12
255
2608
—
—
—
8
15
205
2516
10
36
156
2115
pH of Capillary blood
2745-8 [3009343]
2745-8 [3009343]
1.4e+00
1.8e+00
—
—
—
1.9e+00
1.2e+00
cases:3.82%
controls:0.99%
cases:2.67%
controls:0.46%
—
—
—
—
—
—
cases:3.76%
controls:0.59%
cases:5.42%
controls:1.67%
10
26
252
2594
7
12
255
2608
—
—
—
8
15
205
2516
9
36
157
2115
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
8.5e-01
1.2e+00
2.0e+00
—
—
1.0e+00
5.9e-01
cases:13.36%
controls:6.18%
cases:11.83%
controls:3.93%
cases:3.44%
controls:0.50%
—
—
—
—
cases:8.92%
controls:3.48%
cases:17.47%
controls:10.51%
35
162
227
2458
31
103
231
2517
9
13
253
2607
—
—
19
88
194
2443
29
226
137
1925
Specific gravity of Urine by Refractometry
5810-7 [3019150]
5810-7 [3019150]
8.2e-01
1.4e+00
2.8e+00
—
—
5.8e-01
4.5e-01
cases:9.54%
controls:4.43%
cases:8.40%
controls:2.25%
cases:4.20%
controls:0.27%
—
—
—
—
cases:4.69%
controls:2.69%
cases:12.05%
controls:8.00%
25
116
237
2504
22
59
240
2561
11
7
251
2613
—
—
10
68
203
2463
20
172
146
1979
Pain in limb
M79.6 [45587063]
M79.6 [45587063]
9.2e-01
1.7e+00
—
—
—
1.4e+00
1.0e+00
cases:11.45%
controls:4.92%
cases:8.40%
controls:1.68%
—
—
—
—
—
—
cases:7.98%
controls:2.17%
cases:18.67%
controls:7.58%
30
129
232
2491
22
44
240
2576
—
—
—
17
55
196
2476
31
163
135
1988
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
N02BA01 [21604305]
1.3e+00
1.1e+00
1.5e+00
—
1.4e+00
1.4e+00
1.0e+00
cases:8.78%
controls:2.44%
cases:4.96%
controls:1.64%
cases:2.29%
controls:0.53%
—
—
cases:2.37%
controls:0.57%
cases:6.10%
controls:1.54%
cases:9.04%
controls:3.44%
23
64
239
2556
13
43
249
2577
6
14
256
2606
—
6
15
247
2594
13
39
200
2492
15
74
151
2077
Implementation of podiatry rehabilitation plan
SPAT1225 [2001700326]
SPAT1225 [2001700326]
2.1e+00
2.8e+00
—
—
—
—
—
cases:3.44%
controls:0.42%
cases:3.05%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
9
11
253
2609
8
5
254
2615
—
—
—
—
—
digoxin; oral, parenteral
C01AA05 [21600234]
C01AA05 [21600234]
1.4e+00
1.9e+00
1.5e+00
—
—
1.6e+00
1.2e+00
cases:7.25%
controls:1.83%
cases:8.40%
controls:1.37%
cases:2.29%
controls:0.50%
—
—
—
—
cases:5.63%
controls:1.19%
cases:4.82%
controls:1.49%
19
48
243
2572
22
36
240
2584
6
13
256
2607
—
—
12
30
201
2501
8
32
158
2119
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
5.4e-01
7.5e-01
1.7e+00
—
1.6e+00
8.4e-01
6.5e-01
cases:11.45%
controls:7.02%
cases:11.07%
controls:5.53%
cases:6.11%
controls:1.18%
—
—
cases:6.32%
controls:1.30%
cases:13.62%
controls:6.36%
cases:21.69%
controls:12.60%
30
184
232
2436
29
145
233
2475
16
31
246
2589
—
16
34
237
2575
29
161
184
2370
36
271
130
1880
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
7.4e-01
1.5e+00
2.7e+00
—
1.3e+00
5.3e-01
3.2e-01
cases:12.98%
controls:6.64%
cases:12.98%
controls:3.28%
cases:5.34%
controls:0.38%
—
—
cases:2.37%
controls:0.65%
cases:6.57%
controls:3.99%
cases:16.27%
controls:12.37%
34
174
228
2446
34
86
228
2534
14
10
248
2610
—
6
17
247
2592
14
101
199
2430
27
266
139
1885
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
14196-0 [3023520]
1.3e+00
2.3e+00
—
—
—
—
1.3e+00
cases:4.58%
controls:1.30%
cases:3.44%
controls:0.34%
—
—
—
—
—
—
—
—
cases:7.23%
controls:2.14%
12
34
250
2586
9
9
253
2611
—
—
—
—
12
46
154
2105
Lactate [Moles/volume] in Arterial blood
2518-9 [3018405]
2518-9 [3018405]
2.2e+00
2.7e+00
—
—
—
—
—
cases:2.29%
controls:0.27%
cases:2.67%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
6
7
256
2613
7
5
255
2615
—
—
—
—
—
Pure hypercholesterolaemia
E78.01 [2000501514]
E78.01 [2000501514]
1.2e+00
2.0e+00
—
—
—
1.6e+00
4.8e-01
cases:8.40%
controls:2.75%
cases:9.54%
controls:1.41%
—
—
—
—
—
—
cases:6.10%
controls:1.26%
cases:8.43%
controls:5.39%
22
72
240
2548
25
37
237
2583
—
—
—
13
32
200
2499
14
116
152
2035
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
SPAT1222 [2001700323]
1.5e+00
1.9e+00
—
—
1.7e+00
1.4e+00
8.7e-01
cases:7.25%
controls:1.64%
cases:7.25%
controls:1.18%
—
—
—
—
cases:2.77%
controls:0.54%
cases:5.63%
controls:1.50%
cases:7.83%
controls:3.44%
19
43
243
2577
19
31
243
2589
—
—
7
14
246
2595
12
38
201
2493
13
74
153
2077
insulin lispro; parenteral
A10AC04 [21600726]
A10AC04 [21600726]
1.7e+00
1.5e+00
—
—
1.7e+00
1.3e+00
1.6e+00
cases:8.02%
controls:1.53%
cases:5.73%
controls:1.37%
—
—
—
—
cases:1.98%
controls:0.38%
cases:4.23%
controls:1.19%
cases:7.23%
controls:1.58%
21
40
241
2580
15
36
247
2584
—
—
5
10
248
2599
9
30
204
2501
12
34
154
2117
insulin lispro; parenteral
A10AB04 [21600718]
A10AB04 [21600718]
1.7e+00
1.5e+00
—
—
1.7e+00
1.3e+00
1.6e+00
cases:8.02%
controls:1.53%
cases:5.73%
controls:1.37%
—
—
—
—
cases:1.98%
controls:0.38%
cases:4.23%
controls:1.19%
cases:7.23%
controls:1.58%
21
40
241
2580
15
36
247
2584
—
—
5
10
248
2599
9
30
204
2501
12
34
154
2117
Leg/thigh symptom/complaint
L14 [2002000638]
L14 [2002000638]
1.3e+00
—
—
—
—
2.7e+00
2.1e+00
cases:2.29%
controls:0.65%
—
—
—
—
—
—
—
—
cases:2.82%
controls:0.20%
cases:6.63%
controls:0.88%
6
17
256
2603
—
—
—
—
6
5
207
2526
11
19
155
2132
insulin lispro; parenteral
A10AD04 [21600732]
A10AD04 [21600732]
1.7e+00
1.5e+00
—
—
1.7e+00
1.3e+00
1.6e+00
cases:7.63%
controls:1.53%
cases:5.73%
controls:1.37%
—
—
—
—
cases:1.98%
controls:0.38%
cases:4.23%
controls:1.19%
cases:7.23%
controls:1.53%
20
40
242
2580
15
36
247
2584
—
—
5
10
248
2599
9
30
204
2501
12
33
154
2118
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
E11.9 [45561952]
1.3e+00
1.4e+00
1.2e+00
1.0e+50
2.0e+00
8.5e-01
7.2e-01
cases:20.23%
controls:6.18%
cases:11.07%
controls:3.02%
cases:1.91%
controls:0.61%
cases:2.67%
controls:0.00%
cases:2.77%
controls:0.38%
cases:6.57%
controls:2.92%
cases:14.46%
controls:7.58%
53
162
209
2458
29
79
233
2541
5
16
257
2604
7
0
255
2620
7
10
246
2599
14
74
199
2457
24
163
142
1988
Base excess in Venous blood by calculation
1927-3 [3002032]
1927-3 [3002032]
1.5e+00
2.0e+00
—
—
—
1.2e+00
1.2e+00
cases:6.49%
controls:1.53%
cases:5.73%
controls:0.84%
—
—
—
—
—
—
cases:3.29%
controls:0.99%
cases:9.04%
controls:2.79%
17
40
245
2580
15
22
247
2598
—
—
—
7
25
206
2506
15
60
151
2091
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
2021-4 [3021447]
1.4e+00
2.0e+00
—
—
—
1.2e+00
1.3e+00
cases:6.11%
controls:1.53%
cases:5.73%
controls:0.80%
—
—
—
—
—
—
cases:3.29%
controls:0.99%
cases:9.04%
controls:2.74%
16
40
246
2580
15
21
247
2599
—
—
—
7
25
206
2506
15
59
151
2092
Body temperature
8310-5 [3020891]
8310-5 [3020891]
2.2e+00
2.5e+00
—
—
—
—
1.3e+00
cases:2.67%
controls:0.31%
cases:2.67%
controls:0.23%
—
—
—
—
—
—
—
—
cases:3.01%
controls:0.84%
7
8
255
2612
7
6
255
2614
—
—
—
—
5
18
161
2133
ECG with 12 standard connections
XF400 [2001303368]
XF400 [2001303368]
8.8e-01
2.0e+00
—
—
—
2.7e+00
1.1e+00
cases:5.34%
controls:2.29%
cases:3.82%
controls:0.53%
—
—
—
—
—
—
cases:3.29%
controls:0.24%
cases:5.42%
controls:1.86%
14
60
248
2560
10
14
252
2606
—
—
—
7
6
206
2525
9
40
157
2111
pH of Venous blood
2746-6 [3012544]
2746-6 [3012544]
1.4e+00
2.0e+00
—
—
—
1.2e+00
1.3e+00
cases:6.11%
controls:1.64%
cases:5.73%
controls:0.80%
—
—
—
—
—
—
cases:3.29%
controls:0.99%
cases:9.64%
controls:2.88%
16
43
246
2577
15
21
247
2599
—
—
—
7
25
206
2506
16
62
150
2089
Microscopic observation [Identifier] in Isolate by Gram stain
87975-9 [36305247]
87975-9 [36305247]
2.2e+00
—
1.0e+50
—
—
—
2.4e+00
cases:3.44%
controls:0.38%
—
—
cases:1.91%
controls:0.00%
—
—
—
—
—
—
cases:3.01%
controls:0.28%
9
10
253
2610
—
5
0
257
2620
—
—
—
5
6
161
2145
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
59275-8 [40762366]
9.8e-01
2.1e+00
1.0e+50
—
—
2.5e+00
9.7e-01
cases:1.91%
controls:0.73%
cases:3.44%
controls:0.42%
cases:1.91%
controls:0.00%
—
—
—
—
cases:2.82%
controls:0.24%
cases:3.61%
controls:1.39%
5
19
257
2601
9
11
253
2609
5
0
257
2620
—
—
6
6
207
2525
6
30
160
2121
saccharomyces boulardii; oral
A07FA02 [21600670]
A07FA02 [21600670]
2.1e+00
2.5e+00
—
—
—
—
1.5e+00
cases:4.58%
controls:0.57%
cases:2.29%
controls:0.19%
—
—
—
—
—
—
—
—
cases:3.61%
controls:0.84%
12
15
250
2605
6
5
256
2615
—
—
—
—
6
18
160
2133
Diabetes non-insulin dependent
T90 [2002001131]
T90 [2002001131]
1.2e+00
1.3e+00
1.2e+00
—
1.2e+00
9.9e-01
1.1e+00
cases:18.32%
controls:6.30%
cases:12.21%
controls:3.66%
cases:3.44%
controls:1.03%
—
—
cases:3.56%
controls:1.07%
cases:10.33%
controls:4.11%
cases:19.88%
controls:7.81%
48
165
214
2455
32
96
230
2524
9
27
253
2593
—
9
28
244
2581
22
104
191
2427
33
168
133
1983
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
1.0e+00
1.2e+00
—
—
—
1.5e+00
8.8e-01
cases:12.60%
controls:4.92%
cases:6.87%
controls:2.25%
—
—
—
—
—
—
cases:6.57%
controls:1.58%
cases:15.06%
controls:6.88%
33
129
229
2491
18
59
244
2561
—
—
—
14
40
199
2491
25
148
141
2003
prazosin; oral
C02CA01 [21600411]
C02CA01 [21600411]
2.7e+00
1.9e+00
-1.0e+50
—
—
1.5e+00
1.5e+00
cases:5.73%
controls:0.42%
cases:2.67%
controls:0.42%
cases:0.00%
controls:0.23%
—
—
—
—
cases:2.82%
controls:0.67%
cases:4.22%
controls:0.93%
15
11
247
2609
7
11
255
2609
0
6
262
2614
—
—
6
17
207
2514
7
20
159
2131
Functional capacity evaluation
443351003 [40481051]
443351003 [40481051]
1.2e+00
1.9e+00
—
—
—
1.2e+00
1.4e+00
cases:7.25%
controls:2.25%
cases:6.11%
controls:0.99%
—
—
—
—
—
—
cases:4.23%
controls:1.34%
cases:10.24%
controls:2.70%
19
59
243
2561
16
26
246
2594
—
—
—
9
34
204
2497
17
58
149
2093
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
2714-4 [3014007]
1.9e+00
2.6e+00
—
—
—
—
1.3e+00
cases:2.67%
controls:0.42%
cases:4.58%
controls:0.34%
—
—
—
—
—
—
—
—
cases:4.22%
controls:1.21%
7
11
255
2609
12
9
250
2611
—
—
—
—
7
26
159
2125
insulin glulisine; parenteral
A10AB06 [21600720]
A10AB06 [21600720]
2.5e+00
2.0e+00
—
—
—
—
—
cases:3.05%
controls:0.27%
cases:2.29%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
8
7
254
2613
6
8
256
2612
—
—
—
—
—
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
N02AE01 [21604287]
1.5e+00
1.6e+00
1.7e+00
—
—
1.3e+00
9.5e-01
cases:8.78%
controls:2.02%
cases:6.49%
controls:1.37%
cases:1.91%
controls:0.34%
—
—
—
—
cases:5.63%
controls:1.54%
cases:8.43%
controls:3.44%
23
53
239
2567
17
36
245
2584
5
9
257
2611
—
—
12
39
201
2492
14
74
152
2077
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
4.6e-01
6.8e-01
1.2e+00
—
1.9e+00
7.0e-01
5.0e-01
cases:21.76%
controls:14.92%
cases:15.27%
controls:8.36%
cases:4.58%
controls:1.37%
—
—
cases:6.32%
controls:1.03%
cases:15.02%
controls:8.10%
cases:30.72%
controls:21.15%
57
391
205
2229
40
219
222
2401
12
36
250
2584
—
16
27
237
2582
32
205
181
2326
51
455
115
1696
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
2030-5 [3028653]
1.8e+00
2.6e+00
—
—
—
—
1.0e+00
cases:2.67%
controls:0.46%
cases:4.58%
controls:0.34%
—
—
—
—
—
—
—
—
cases:3.61%
controls:1.35%
7
12
255
2608
12
9
250
2611
—
—
—
—
6
29
160
2122
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
4679-7 [3027945]
1.1e+00
2.2e+00
—
—
—
9.2e-01
1.1e+00
cases:6.11%
controls:2.02%
cases:4.20%
controls:0.50%
—
—
—
—
—
—
cases:2.35%
controls:0.95%
cases:8.43%
controls:3.02%
16
53
246
2567
11
13
251
2607
—
—
—
5
24
208
2507
14
65
152
2086
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
6.8e-01
1.2e+00
2.5e+00
—
1.3e+00
6.6e-01
3.1e-01
cases:15.27%
controls:8.36%
cases:14.89%
controls:4.96%
cases:6.49%
controls:0.57%
—
—
cases:3.16%
controls:0.84%
cases:10.33%
controls:5.61%
cases:20.48%
controls:15.95%
40
219
222
2401
39
130
223
2490
17
15
245
2605
—
8
22
245
2587
22
142
191
2389
34
343
132
1808
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
14675-3 [3036481]
5.5e-01
2.0e+00
—
—
—
2.3e+00
6.1e-01
cases:2.29%
controls:1.34%
cases:3.05%
controls:0.42%
—
—
—
—
—
—
cases:4.23%
controls:0.43%
cases:3.61%
controls:2.00%
6
35
256
2585
8
11
254
2609
—
—
—
9
11
204
2520
6
43
160
2108
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 [3005895]
2639-3 [3005895]
1.9e+00
—
—
—
—
—
2.5e+00
cases:3.82%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:6.63%
controls:0.60%
10
16
252
2604
—
—
—
—
—
11
13
155
2138
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
5.9e-01
1.3e+00
1.9e+00
—
—
1.1e+00
6.2e-01
cases:7.25%
controls:4.16%
cases:9.16%
controls:2.71%
cases:2.67%
controls:0.42%
—
—
—
—
cases:7.51%
controls:2.53%
cases:12.65%
controls:7.25%
19
109
243
2511
24
71
238
2549
7
11
255
2609
—
—
16
64
197
2467
21
156
145
1995
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
1.4e+00
1.6e+00
—
—
—
1.3e+00
1.3e+00
cases:7.63%
controls:2.06%
cases:6.11%
controls:1.26%
—
—
—
—
—
—
cases:2.82%
controls:0.75%
cases:9.04%
controls:2.65%
20
54
242
2566
16
33
246
2587
—
—
—
6
19
207
2512
15
57
151
2094
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
7.2e-01
1.2e+00
2.1e+00
—
—
9.6e-01
5.0e-01
cases:9.92%
controls:5.08%
cases:9.92%
controls:3.24%
cases:3.44%
controls:0.42%
—
—
—
—
cases:7.98%
controls:3.20%
cases:15.06%
controls:9.72%
26
133
236
2487
26
85
236
2535
9
11
253
2609
—
—
17
81
196
2450
25
209
141
1942
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
75622-1 [46235355]
1.3e+00
1.4e+00
—
—
—
1.6e+00
1.6e+00
cases:6.87%
controls:2.06%
cases:3.82%
controls:0.95%
—
—
—
—
—
—
cases:2.82%
controls:0.59%
cases:11.45%
controls:2.51%
18
54
244
2566
10
25
252
2595
—
—
—
6
15
207
2516
19
54
147
2097
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
6.4e-01
1.2e+00
2.4e+00
—
1.4e+00
7.0e-01
3.3e-01
cases:14.50%
controls:8.24%
cases:14.50%
controls:4.85%
cases:6.11%
controls:0.57%
—
—
cases:3.16%
controls:0.80%
cases:10.33%
controls:5.41%
cases:20.48%
controls:15.62%
38
216
224
2404
38
127
224
2493
16
15
246
2605
—
8
21
245
2588
22
137
191
2394
34
336
132
1815
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
1960-4 [3008152]
1.8e+00
2.4e+00
—
—
—
—
1.2e+00
cases:4.58%
controls:0.76%
cases:4.96%
controls:0.46%
—
—
—
—
—
—
—
—
cases:4.82%
controls:1.53%
12
20
250
2600
13
12
249
2608
—
—
—
—
8
33
158
2118
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
TPH15 [2001309600]
1.9e+00
2.3e+00
—
—
—
—
2.4e+00
cases:2.67%
controls:0.42%
cases:1.91%
controls:0.19%
—
—
—
—
—
—
—
—
cases:4.82%
controls:0.46%
7
11
255
2609
5
5
257
2615
—
—
—
—
8
10
158
2141
Gas panel - Arterial blood
24336-0 [3019060]
24336-0 [3019060]
1.8e+00
2.4e+00
—
—
—
—
7.2e-01
cases:4.58%
controls:0.80%
cases:3.82%
controls:0.34%
—
—
—
—
—
—
—
—
cases:3.01%
controls:1.49%
12
21
250
2599
10
9
252
2611
—
—
—
—
5
32
161
2119
Ultrasound examination of lower leg veins
PH2AE [2001309451]
PH2AE [2001309451]
1.8e+00
2.3e+00
—
—
—
1.8e+00
1.2e+00
cases:7.63%
controls:1.30%
cases:3.82%
controls:0.38%
—
—
—
—
—
—
cases:2.35%
controls:0.40%
cases:5.42%
controls:1.67%
20
34
242
2586
10
10
252
2610
—
—
—
5
10
208
2521
9
36
157
2115
ferrous glycine sulfate; oral
B03AA01 [21601080]
B03AA01 [21601080]
2.4e+00
1.7e+00
—
—
—
1.8e+00
7.2e-01
cases:6.49%
controls:0.65%
cases:2.67%
controls:0.50%
—
—
—
—
—
—
cases:3.29%
controls:0.55%
cases:3.01%
controls:1.49%
17
17
245
2603
7
13
255
2607
—
—
—
7
14
206
2517
5
32
161
2119
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
4.4e-01
9.7e-01
1.7e+00
—
1.5e+00
6.3e-01
4.7e-01
cases:20.61%
controls:14.35%
cases:16.79%
controls:7.14%
cases:6.11%
controls:1.18%
—
—
cases:5.53%
controls:1.30%
cases:12.68%
controls:7.15%
cases:30.12%
controls:21.20%
54
376
208
2244
44
187
218
2433
16
31
246
2589
—
14
34
239
2575
27
181
186
2350
50
456
116
1695
ezetimibe; oral
C10AX09 [21601896]
C10AX09 [21601896]
1.6e+00
1.5e+00
1.1e+00
—
—
9.3e-01
1.1e+00
cases:8.40%
controls:1.79%
cases:8.02%
controls:1.98%
cases:1.91%
controls:0.65%
—
—
—
—
cases:5.63%
controls:2.29%
cases:9.64%
controls:3.58%
22
47
240
2573
21
52
241
2568
5
17
257
2603
—
—
12
58
201
2473
16
77
150
2074
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
5.7e-01
1.2e+00
1.9e+00
—
—
1.1e+00
6.9e-01
cases:7.63%
controls:4.47%
cases:8.78%
controls:2.94%
cases:2.67%
controls:0.42%
—
—
—
—
cases:7.51%
controls:2.69%
cases:13.86%
controls:7.48%
20
117
242
2503
23
77
239
2543
7
11
255
2609
—
—
16
68
197
2463
23
161
143
1990
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
FM1EE [2001303307]
1.3e+00
1.1e+00
—
—
—
1.7e+00
1.1e+00
cases:12.60%
controls:3.63%
cases:4.96%
controls:1.76%
—
—
—
—
—
—
cases:4.23%
controls:0.83%
cases:10.84%
controls:4.00%
33
95
229
2525
13
46
249
2574
—
—
—
9
21
204
2510
18
86
148
2065
Bloodpressure measurement
XF600 [2001303376]
XF600 [2001303376]
2.1e+00
—
—
—
—
—
2.0e+00
cases:4.20%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:4.22%
controls:0.60%
11
14
251
2606
—
—
—
—
—
7
13
159
2138
Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]
14627-4 [3027273]
1.6e+00
2.5e+00
—
—
—
—
8.9e-01
cases:3.44%
controls:0.73%
cases:2.67%
controls:0.23%
—
—
—
—
—
—
—
—
cases:4.22%
controls:1.77%
9
19
253
2601
7
6
255
2614
—
—
—
—
7
38
159
2113
Ankle X-ray examination without contrast
NH1AA [2001308235]
NH1AA [2001308235]
1.7e+00
—
—
—
—
—
2.3e+00
cases:3.44%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:4.22%
controls:0.42%
9
17
253
2603
—
—
—
—
—
7
9
159
2142
Atherosclerotic cardiovascular disease, so described
I25.0 [45552783]
I25.0 [45552783]
1.5e+00
2.5e+00
—
—
—
—
—
cases:3.82%
controls:0.88%
cases:2.29%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
10
23
252
2597
6
5
256
2615
—
—
—
—
—
Monitoring of emergency patient
SPAT1104 [2001700205]
SPAT1104 [2001700205]
1.8e+00
2.2e+00
—
—
—
—
1.4e+00
cases:4.20%
controls:0.73%
cases:2.67%
controls:0.31%
—
—
—
—
—
—
—
—
cases:3.61%
controls:0.93%
11
19
251
2601
7
8
255
2612
—
—
—
—
6
20
160
2131
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
4.1e-01
6.8e-01
1.8e+00
—
1.5e+00
4.7e-01
3.3e-01
cases:20.99%
controls:15.00%
cases:16.41%
controls:9.08%
cases:5.73%
controls:0.99%
—
—
cases:3.95%
controls:0.92%
cases:12.68%
controls:8.30%
cases:28.31%
controls:22.04%
55
393
207
2227
43
238
219
2382
15
26
247
2594
—
10
24
243
2585
27
210
186
2321
47
474
119
1677
Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
3216-9 [3020427]
3216-9 [3020427]
1.8e+00
2.2e+00
—
—
—
—
1.8e+00
cases:2.67%
controls:0.46%
cases:2.29%
controls:0.27%
—
—
—
—
—
—
—
—
cases:3.01%
controls:0.51%
7
12
255
2608
6
7
256
2613
—
—
—
—
5
11
161
2140
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
3.0e-01
1.0e+00
1.8e+00
1.0e+50
—
1.0e+00
4.1e-01
cases:8.40%
controls:6.34%
cases:8.02%
controls:2.98%
cases:3.44%
controls:0.57%
cases:1.91%
controls:0.00%
—
—
cases:7.98%
controls:3.00%
cases:16.27%
controls:11.44%
22
166
240
2454
21
78
241
2542
9
15
253
2605
5
0
257
2620
—
17
76
196
2455
27
246
139
1905
No procedures
SPAT1301 [2001700402]
SPAT1301 [2001700402]
1.1e+00
1.4e+00
1.5e+00
—
1.4e+00
1.3e+00
5.4e-01
cases:14.89%
controls:5.46%
cases:8.02%
controls:2.06%
cases:2.67%
controls:0.61%
—
—
cases:1.98%
controls:0.50%
cases:8.45%
controls:2.37%
cases:10.84%
controls:6.60%
39
143
223
2477
21
54
241
2566
7
16
255
2604
—
5
13
248
2596
18
60
195
2471
18
142
148
2009
Pulmonary Disease
29 [38004472]
29 [38004472]
9.8e-01
1.1e+00
1.2e+00
—
—
9.0e-01
8.1e-01
cases:21.37%
controls:9.24%
cases:14.50%
controls:5.19%
cases:2.67%
controls:0.84%
—
—
—
—
cases:11.27%
controls:4.90%
cases:21.69%
controls:10.97%
56
242
206
2378
38
136
224
2484
7
22
255
2598
—
—
24
124
189
2407
36
236
130
1915
Diabetes insulin dependent
T89 [2002001130]
T89 [2002001130]
1.8e+00
1.9e+00
-1.0e+50
—
-1.0e+50
1.3e+00
1.3e+00
cases:4.20%
controls:0.69%
cases:3.82%
controls:0.57%
cases:0.00%
controls:0.19%
—
—
cases:0.00%
controls:0.31%
cases:2.35%
controls:0.67%
cases:4.82%
controls:1.30%
11
18
251
2602
10
15
252
2605
0
5
262
2615
—
0
8
253
2601
5
17
208
2514
8
28
158
2123
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
6.2e-01
1.2e+00
2.5e+00
—
1.3e+00
6.6e-01
2.6e-01
cases:14.89%
controls:8.63%
cases:14.89%
controls:5.04%
cases:6.49%
controls:0.57%
—
—
cases:3.16%
controls:0.84%
cases:10.33%
controls:5.61%
cases:19.88%
controls:16.04%
39
226
223
2394
39
132
223
2488
17
15
245
2605
—
8
22
245
2587
22
142
191
2389
33
345
133
1806
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
1.6e+00
—
—
—
—
—
2.0e+00
cases:4.20%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:1.02%
11
22
251
2598
—
—
—
—
—
12
22
154
2129
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
R5110 [2001310246]
7.1e-01
—
—
—
—
2.2e+00
1.4e+00
cases:3.82%
controls:1.91%
—
—
—
—
—
—
—
—
cases:2.82%
controls:0.32%
cases:7.23%
controls:1.81%
10
50
252
2570
—
—
—
—
6
8
207
2523
12
39
154
2112
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
8.4e-01
1.5e+00
1.6e+00
—
1.9e+00
1.3e+00
7.4e-01
cases:10.69%
controls:4.92%
cases:9.92%
controls:2.29%
cases:1.91%
controls:0.38%
—
—
cases:1.98%
controls:0.31%
cases:7.51%
controls:2.25%
cases:15.66%
controls:8.14%
28
129
234
2491
26
60
236
2560
5
10
257
2610
—
5
8
248
2601
16
57
197
2474
26
175
140
1976
sulfadiazine and trimethoprim
J01EE02 [21602962]
J01EE02 [21602962]
7.1e-01
1.5e+00
—
—
—
2.1e+00
9.3e-01
cases:6.87%
controls:3.51%
cases:4.96%
controls:1.18%
—
—
—
—
—
—
cases:5.16%
controls:0.63%
cases:6.02%
controls:2.46%
18
92
244
2528
13
31
249
2589
—
—
—
11
16
202
2515
10
53
156
2098
amitriptyline; oral, parenteral
N06AA09 [21604696]
N06AA09 [21604696]
1.2e+00
1.4e+00
—
—
—
1.2e+00
1.0e+00
cases:9.54%
controls:3.05%
cases:6.49%
controls:1.76%
—
—
—
—
—
—
cases:5.16%
controls:1.62%
cases:8.43%
controls:3.16%
25
80
237
2540
17
46
245
2574
—
—
—
11
41
202
2490
14
68
152
2083
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
50949-7 [3029937]
6.8e-01
1.2e+00
2.4e+00
—
1.7e+00
9.1e-01
2.6e-01
cases:9.54%
controls:5.08%
cases:8.40%
controls:2.79%
cases:4.20%
controls:0.38%
—
—
cases:2.37%
controls:0.46%
cases:7.51%
controls:3.16%
cases:10.84%
controls:8.55%
25
133
237
2487
22
73
240
2547
11
10
251
2610
—
6
12
247
2597
16
80
197
2451
18
184
148
1967
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
2885-2 [3020630]
1.4e+00
2.2e+00
—
—
—
—
9.6e-01
cases:6.11%
controls:1.64%
cases:4.58%
controls:0.53%
—
—
—
—
—
—
—
—
cases:4.82%
controls:1.91%
16
43
246
2577
12
14
250
2606
—
—
—
—
8
41
158
2110
betamethasone
D07AC01 [21602120]
D07AC01 [21602120]
1.1e+00
1.2e+00
—
—
—
1.3e+00
7.8e-01
cases:14.89%
controls:5.65%
cases:7.63%
controls:2.40%
—
—
—
—
—
—
cases:6.10%
controls:1.82%
cases:14.46%
controls:7.16%
39
148
223
2472
20
63
242
2557
—
—
—
13
46
200
2485
24
154
142
1997
betamethasone
A07EA04 [21600656]
A07EA04 [21600656]
1.1e+00
1.2e+00
—
—
—
1.3e+00
7.8e-01
cases:14.89%
controls:5.65%
cases:7.63%
controls:2.40%
—
—
—
—
—
—
cases:6.10%
controls:1.82%
cases:14.46%
controls:7.16%
39
148
223
2472
20
63
242
2557
—
—
—
13
46
200
2485
24
154
142
1997
betamethasone
C05AA05 [21601610]
C05AA05 [21601610]
1.1e+00
1.2e+00
—
—
—
1.3e+00
7.8e-01
cases:14.89%
controls:5.65%
cases:7.63%
controls:2.40%
—
—
—
—
—
—
cases:6.10%
controls:1.82%
cases:14.46%
controls:7.16%
39
148
223
2472
20
63
242
2557
—
—
—
13
46
200
2485
24
154
142
1997
betamethasone
S02BA07 [21605169]
S02BA07 [21605169]
1.1e+00
1.2e+00
—
—
—
1.3e+00
7.8e-01
cases:14.89%
controls:5.65%
cases:7.63%
controls:2.40%
—
—
—
—
—
—
cases:6.10%
controls:1.82%
cases:14.46%
controls:7.16%
39
148
223
2472
20
63
242
2557
—
—
—
13
46
200
2485
24
154
142
1997
Type 2 diabetes mellitus, with peripheral circulatory complications
E11.5 [45557114]
E11.5 [45557114]
3.5e+00
—
1.0e+50
1.0e+50
1.0e+50
—
—
cases:8.02%
controls:0.27%
—
—
cases:6.11%
controls:0.00%
cases:4.96%
controls:0.00%
cases:6.72%
controls:0.00%
—
—
—
—
21
7
241
2613
—
16
0
246
2620
13
0
249
2620
17
0
236
2609
—
—
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
5.3e-01
1.0e+00
2.4e+00
—
1.3e+00
8.2e-01
4.1e-01
cases:11.83%
controls:7.29%
cases:9.92%
controls:3.74%
cases:4.58%
controls:0.42%
—
—
cases:2.37%
controls:0.69%
cases:8.92%
controls:4.15%
cases:16.87%
controls:11.85%
31
191
231
2429
26
98
236
2522
12
11
250
2609
—
6
18
247
2591
19
105
194
2426
28
255
138
1896
SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
94759-8 [586526]
94759-8 [586526]
1.8e+00
—
—
—
—
1.7e+00
1.7e+00
cases:2.67%
controls:0.46%
—
—
—
—
—
—
—
—
cases:2.35%
controls:0.43%
cases:4.82%
controls:0.93%
7
12
255
2608
—
—
—
—
5
11
208
2520
8
20
158
2131
Body CT examination
JN4AD [2001310897]
JN4AD [2001310897]
1.6e+00
1.9e+00
—
—
—
—
—
cases:3.44%
controls:0.73%
cases:2.67%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
9
19
253
2601
7
11
255
2609
—
—
—
—
—
Anaemia, unspecified
D64.9 [45600610]
D64.9 [45600610]
1.4e+00
2.1e+00
—
—
—
—
6.6e-01
cases:4.96%
controls:1.30%
cases:4.58%
controls:0.61%
—
—
—
—
—
—
—
—
cases:4.82%
controls:2.56%
13
34
249
2586
12
16
250
2604
—
—
—
—
8
55
158
2096
Acute tubulo-interstitial nephritis
N10 [45543856]
N10 [45543856]
1.7e+00
1.7e+00
—
—
—
—
1.0e+00
cases:7.25%
controls:1.37%
cases:3.44%
controls:0.65%
—
—
—
—
—
—
—
—
cases:5.42%
controls:2.00%
19
36
243
2584
9
17
253
2603
—
—
—
—
9
43
157
2108
Hyperlipidaemia, unspecified
E78.5 [45537986]
E78.5 [45537986]
1.6e+00
1.8e+00
—
—
—
—
7.5e-01
cases:4.20%
controls:0.88%
cases:3.44%
controls:0.57%
—
—
—
—
—
—
—
—
cases:3.01%
controls:1.44%
11
23
251
2597
9
15
253
2605
—
—
—
—
5
31
161
2120
Chronic ulcer of skin, not elsewhere classified
L98.4 [45533667]
L98.4 [45533667]
—
—
—
—
—
1.0e+50
3.4e+00
—
—
—
—
—
—
—
—
—
—
cases:4.23%
controls:0.00%
cases:9.04%
controls:0.33%
—
—
—
—
—
9
0
204
2531
15
7
151
2144
Type 1 diabetes mellitus, With renal complications
E10.2 [45586137]
E10.2 [45586137]
3.4e+00
—
—
—
—
—
—
cases:5.34%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
14
5
248
2615
—
—
—
—
—
—
Chronic kidney disease
N18 [45582391]
N18 [45582391]
3.4e+00
—
—
—
—
—
1.6e+00
cases:5.34%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:3.01%
controls:0.60%
14
5
248
2615
—
—
—
—
—
5
13
161
2138
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
14933-6 [3026493]
1.0e+00
1.3e+00
—
—
—
8.5e-01
1.0e+00
cases:12.60%
controls:4.85%
cases:8.02%
controls:2.33%
—
—
—
—
—
—
cases:4.23%
controls:1.86%
cases:15.06%
controls:5.90%
33
127
229
2493
21
61
241
2559
—
—
—
9
47
204
2484
25
127
141
2024
Doppler ultrasound examination of heart
FM1DE [2001303299]
FM1DE [2001303299]
1.5e+00
1.9e+00
—
—
—
—
1.9e+00
cases:4.58%
controls:1.07%
cases:2.29%
controls:0.34%
—
—
—
—
—
—
—
—
cases:6.02%
controls:0.98%
12
28
250
2592
6
9
256
2611
—
—
—
—
10
21
156
2130
Telehealth
OMOP5556618 [722455]
OMOP5556618 [722455]
6.0e-01
6.4e-01
1.3e+00
—
9.3e-01
7.7e-01
5.8e-01
cases:33.97%
controls:22.06%
cases:16.79%
controls:9.58%
cases:5.73%
controls:1.60%
—
—
cases:4.35%
controls:1.76%
cases:17.37%
controls:8.85%
cases:31.33%
controls:20.32%
89
578
173
2042
44
251
218
2369
15
42
247
2578
—
11
46
242
2563
37
224
176
2307
52
437
114
1714
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
5794-3 [3011397]
8.0e-01
1.2e+00
2.1e+00
—
—
4.3e-03
4.3e-01
cases:8.02%
controls:3.78%
cases:7.25%
controls:2.25%
cases:3.05%
controls:0.38%
—
—
—
—
cases:2.82%
controls:2.81%
cases:10.84%
controls:7.35%
21
99
241
2521
19
59
243
2561
8
10
254
2610
—
—
6
71
207
2460
18
158
148
1993
omeprazole; oral, parenteral
A02BC01 [21600096]
A02BC01 [21600096]
6.6e-01
1.1e+00
—
—
—
1.2e+00
1.0e+00
cases:9.54%
controls:5.15%
cases:7.63%
controls:2.71%
—
—
—
—
—
—
cases:6.57%
controls:2.05%
cases:10.24%
controls:3.95%
25
135
237
2485
20
71
242
2549
—
—
—
14
52
199
2479
17
85
149
2066
Other seropositive rheumatoid arthritis
M05.8 [45538634]
M05.8 [45538634]
1.5e+00
1.8e+00
—
—
—
—
1.6e+00
cases:3.82%
controls:0.84%
cases:3.05%
controls:0.53%
—
—
—
—
—
—
—
—
cases:4.22%
controls:0.88%
10
22
252
2598
8
14
254
2606
—
—
—
—
7
19
159
2132
Other specified special examinations
Z01.8 [45581003]
Z01.8 [45581003]
9.4e-01
1.6e+00
—
—
—
1.7e+00
1.1e+00
cases:6.11%
controls:2.48%
cases:3.44%
controls:0.73%
—
—
—
—
—
—
cases:3.76%
controls:0.71%
cases:7.23%
controls:2.65%
16
65
246
2555
9
19
253
2601
—
—
—
8
18
205
2513
12
57
154
2094
Asthma, unspecified
J45.9 [45562456]
J45.9 [45562456]
1.1e+00
1.2e+00
2.2e+00
—
—
1.1e+00
8.1e-01
cases:8.78%
controls:3.13%
cases:4.20%
controls:1.30%
cases:2.29%
controls:0.27%
—
—
—
—
cases:4.23%
controls:1.38%
cases:9.04%
controls:4.23%
23
82
239
2538
11
34
251
2586
6
7
256
2613
—
—
9
35
204
2496
15
91
151
2060
Urinary tract infection, site not specified
N39.0 [45548665]
N39.0 [45548665]
1.3e+00
1.3e+00
—
—
—
2.0e+00
2.8e-01
cases:5.34%
controls:1.53%
cases:2.29%
controls:0.65%
—
—
—
—
—
—
cases:3.29%
controls:0.47%
cases:3.61%
controls:2.74%
14
40
248
2580
6
17
256
2603
—
—
—
7
12
206
2519
6
59
160
2092
isosorbide mononitrate; oral
C01DA14 [21600324]
C01DA14 [21600324]
1.1e+00
1.2e+00
9.7e-01
—
5.8e-01
9.7e-01
8.1e-01
cases:14.12%
controls:5.34%
cases:12.60%
controls:4.12%
cases:2.29%
controls:0.88%
—
—
cases:2.37%
controls:1.34%
cases:9.86%
controls:3.99%
cases:12.05%
controls:5.72%
37
140
225
2480
33
108
229
2512
6
23
256
2597
—
6
35
247
2574
21
101
192
2430
20
123
146
2028
Creatine kinase.MB [Mass/volume] in Serum or Plasma
13969-1 [3005785]
13969-1 [3005785]
1.3e+00
1.9e+00
—
—
—
—
1.0e+00
cases:5.34%
controls:1.45%
cases:5.34%
controls:0.84%
—
—
—
—
—
—
—
—
cases:5.42%
controls:2.05%
14
38
248
2582
14
22
248
2598
—
—
—
—
9
44
157
2107
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
4548-4 [3004410]
3.0e-01
6.2e-01
1.6e+00
—
1.0e+00
3.3e-01
2.2e-01
cases:28.63%
controls:22.82%
cases:26.72%
controls:16.37%
cases:7.63%
controls:1.72%
—
—
cases:5.53%
controls:2.03%
cases:23.00%
controls:17.66%
cases:40.96%
controls:35.75%
75
598
187
2022
70
429
192
2191
20
45
242
2575
—
14
53
239
2556
49
447
164
2084
68
769
98
1382
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
Z03.9 [45552062]
1.3e+00
9.8e-01
—
—
—
1.9e+00
9.7e-01
cases:8.78%
controls:2.56%
cases:1.91%
controls:0.73%
—
—
—
—
—
—
cases:4.23%
controls:0.67%
cases:9.04%
controls:3.63%
23
67
239
2553
5
19
257
2601
—
—
—
9
17
204
2514
15
78
151
2073
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
16128-1 [3017143]
1.4e+00
1.5e+00
—
—
—
1.5e+00
1.8e+00
cases:6.11%
controls:1.56%
cases:2.67%
controls:0.61%
—
—
—
—
—
—
cases:2.35%
controls:0.55%
cases:9.04%
controls:1.67%
16
41
246
2579
7
16
255
2604
—
—
—
5
14
208
2517
15
36
151
2115
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
24351-9 [3004588]
1.3e+00
1.9e+00
—
—
—
—
8.8e-01
cases:5.34%
controls:1.56%
cases:2.67%
controls:0.42%
—
—
—
—
—
—
—
—
cases:3.61%
controls:1.53%
14
41
248
2579
7
11
255
2609
—
—
—
—
6
33
160
2118
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
68438-1 [40771025]
8.7e-01
8.5e-01
2.2e+00
—
1.7e+00
6.7e-01
6.4e-01
cases:12.21%
controls:5.50%
cases:7.25%
controls:3.24%
cases:3.05%
controls:0.34%
—
—
cases:1.98%
controls:0.38%
cases:7.51%
controls:3.99%
cases:20.48%
controls:11.99%
32
144
230
2476
19
85
243
2535
8
9
254
2611
—
5
10
248
2599
16
101
197
2430
34
258
132
1893
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
A10AC30 [21600727]
1.6e+00
1.5e+00
—
—
—
—
1.0e+00
cases:5.34%
controls:1.15%
cases:3.82%
controls:0.88%
—
—
—
—
—
—
—
—
cases:3.61%
controls:1.35%
14
30
248
2590
10
23
252
2597
—
—
—
—
6
29
160
2122
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
UJD10 [2001304788]
7.1e-01
1.4e+00
-1.0e+50
—
—
1.6e+00
4.9e-01
cases:8.02%
controls:4.12%
cases:5.34%
controls:1.34%
cases:0.00%
controls:0.27%
—
—
—
—
cases:5.16%
controls:1.07%
cases:7.23%
controls:4.56%
21
108
241
2512
14
35
248
2585
0
7
262
2613
—
—
11
27
202
2504
12
98
154
2053
Severe anaemia associated with chronic renal failure
138 [2001600134]
138 [2001600134]
3.0e+00
—
—
—
—
—
—
cases:3.82%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
10
5
252
2615
—
—
—
—
—
—
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
35
33
12.09
32.92
1.7
1.1
—
—
—
0
0
63
155
5.03
24.87
2.3
1.4
—
—
—
0
0
84
282
3.91
21.84
17.2
4.9
1.22
1.01
mmol/l
5.48
78
256
74
261
3.56
17.49
10.0
6.4
0.77
0.94
mmol/l
0.13
62
214
87
353
3.19
16.27
6.2
2.2
2.02
2.26
g/l
2.67
81
317
28
49
6.28
15.75
3.5
1.2
—
—
—
0
0
158
909
2.86
15.33
6.3
2.5
—
—
estimate
—
0
0
113
549
2.86
15.11
3.8
2.0
3.66
3.19
mg/l
0.93
105
472
85
382
2.81
12.84
6.2
3.1
0.81
0.81
mmol/l
0.00
79
364
87
399
2.77
12.62
2.9
1.9
—
—
—
0
0
96
480
2.58
11.56
6.3
2.3
—
—
—
0
0
167
1091
2.46
11.02
34.8
13.4
1.32
1.27
inr
0.53
151
919
58
229
2.97
10.97
7.5
3.6
—
—
—
0
0
53
201
3.05
10.75
2.6
2.6
4.44
7.72
ug/l
1.16
47
175
68
309
2.62
9.77
2.4
1.8
—
—
—
0
0
117
684
2.28
9.58
4.0
2.3
56.55
68.78
u/l
0.61
110
631
150
981
2.24
9.23
13.0
4.2
31.16
35.49
g/l
11.86
142
930
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
24
59
4.38
9.20
5.6
2.1
0.28
0.37
iu/ml
0.63
16
32
26
69
4.07
9.03
1.2
1.2
—
—
—
0
0
63
295
2.50
8.40
2.4
1.8
—
—
—
0
0
55
242
2.61
8.34
15.0
3.2
1.02
1.86
mmol/l
0.97
47
202
20
46
4.62
8.30
3.6
3.1
0.89
0.77
nmol/l
0.22
14
40
55
246
2.56
8.05
11.6
3.2
5.84
5.69
kpa
0.57
55
236
44
180
2.74
7.67
4.6
2.9
65.06
66.21
g/l
0.48
37
166
74
397
2.20
7.12
2.0
1.8
1258.59
1201.80
nmol/l
0.21
61
314
38
151
2.77
6.98
2.1
1.8
—
—
—
0
0
98
591
2.05
6.93
4.0
2.7
384.89
356.03
umol/l
1.48
90
510
160
1148
2.01
6.90
8.1
6.2
9.63
11.97
umol/l
3.99
154
1087
17
41
4.36
6.65
1.4
1.4
—
—
—
0
0
17
41
4.36
6.65
1.4
1.4
—
—
—
0
0
34
131
2.83
6.61
6.1
3.6
1.62
2.02
mmol/l
0.34
26
92
30
110
2.95
6.37
2.5
1.8
2.08
1.53
g/l
1.39
23
100
34
139
2.66
5.90
2.0
1.3
—
—
—
0
0
75
439
1.99
5.59
5.8
3.8
575.68
247.81
ng/l
0.31
66
348
108
722
1.84
5.34
3.8
3.2
25.88
31.15
u/l
2.92
102
679
115
784
1.83
5.34
4.0
3.1
4030.54
1488.88
ng/l
1.63
101
659
11
15
7.60
5.19
4.6
3.2
—
—
—
0
0
148
1099
1.80
5.10
22.7
6.4
1.18
1.21
mmol/l
3.87
134
934
131
940
1.79
5.05
6.3
2.7
199.79
148.38
ug/l
1.42
124
871
136
997
1.76
4.79
17.1
5.6
1.18
1.21
mmol/l
4.85
130
906
13
27
5.01
4.56
1.2
1.3
—
—
—
0
0
9
12
7.72
4.39
5.2
1.2
—
—
—
0
0
21
80
2.77
4.18
3.8
2.2
—
—
—
0
0
31
594
0.46
4.16
2.3
3.2
0.57
0.81
ug/l
0.91
17
385
14
37
3.94
3.96
2.3
1.4
—
—
—
0
0
153
1198
1.67
3.93
13.2
9.5
5.47
4.25
e9/l
5.95
140
1047
130
978
1.65
3.90
2.6
2.1
97.86
94.93
pmol/l
0.30
78
518
22
91
2.55
3.75
1.9
2.6
8.29
7.36
g/l
1.51
22
81
22
91
2.55
3.75
1.9
2.6
4.15
4.29
g/l
0.29
22
81
22
91
2.55
3.75
1.9
2.6
3.73
3.85
g/l
0.11
22
81
45
254
1.93
3.63
2.5
2.7
4.76
8.22
umol/l
2.74
40
228
19
75
2.65
3.55
1.9
2.7
10.84
10.51
g/l
0.20
19
65
8
13
6.31
3.52
2.6
1.8
—
—
—
0
0
34
178
2.05
3.38
7.2
3.0
48.82
61.42
ml/min/173m2
1.12
22
72
18
71
2.65
3.37
1.5
1.6
—
—
—
0
0
13
43
3.13
3.30
1.5
1.4
—
—
—
0
0
13
39
3.45
3.27
10.8
5.0
179.00
352.00
iu/ml
—
5
5
6
199
0.29
3.24
1.8
2.2
3.75
3.48
ratio
—
6
162
20
85
2.46
3.24
1.9
2.7
3.12
2.92
g/l
0.44
20
75
7
11
6.50
3.20
6.9
1.6
169.69
80.61
ng/l
—
7
11
14
50
2.90
3.14
2.1
1.2
—
—
—
0
0
18
74
2.54
3.12
2.1
2.6
281.40
115.92
ug/min
—
10
41
72
489
1.65
3.10
2.6
1.7
1.48
1.38
mg/l
0.11
63
404
18
75
2.50
3.04
3.8
1.9
—
—
—
0
0
98
723
1.57
2.99
6.3
3.3
2.30
2.35
mmol/l
3.59
89
652
71
485
1.64
2.98
7.4
3.9
1.02
1.02
kg/l
0.98
55
318
103
770
1.56
2.96
6.6
4.0
50.14
8.66
mg/mmol
3.97
77
502
87
626
1.58
2.95
5.3
3.2
0.57
0.38
e6/l
0.33
73
468
186
2088
0.62
2.88
7.8
6.1
2.27
2.64
mmol/l
5.90
178
1916
17
71
2.49
2.86
1.6
1.6
—
—
—
0
0
118
917
1.52
2.80
3.9
2.3
71.54
76.12
nmol/l
1.08
108
810
179
2017
0.64
2.66
6.8
5.3
7.34
6.07
mmol/l
6.55
167
1835
182
2043
0.64
2.65
6.6
5.2
1.22
1.41
mmol/l
8.75
174
1869
5
7
7.25
2.56
2.0
3.6
0.62
0.60
mmol/l
—
5
7
56
797
0.62
2.55
3.8
4.6
22.87
21.72
%
0.18
24
385
21
102
2.15
2.55
1.5
3.3
4.09
4.23
pmol/l
0.26
16
92
11
37
3.06
2.52
1.5
1.4
—
—
—
0
0
7
16
4.46
2.49
1.1
1.2
—
—
—
0
0
7
16
4.46
2.49
1.0
1.0
—
—
—
0
0
7
16
4.46
2.49
1.1
1.1
99.86
104.25
%
—
7
16
8
22
3.72
2.38
3.3
1.7
1972.38
578.82
mg
—
8
22
89
672
1.49
2.35
2.4
1.7
16.04
20.66
nmol/l
3.22
80
546
19
92
2.15
2.33
3.2
2.7
—
—
—
0
0
36
222
1.72
2.20
2.4
1.8
1.59
1.61
%
0.05
30
199
185
2049
0.67
2.20
6.7
5.3
4.05
4.51
mmol/l
7.00
178
1890
31
184
1.78
2.16
3.9
2.1
37.65
35.08
u/l
0.09
26
155
77
996
0.68
2.14
4.2
5.3
1.95
2.69
ug/l
0.64
63
901
7
20
3.57
2.07
1.4
1.3
—
—
—
0
0
25
142
1.84
2.01
7.6
2.4
0.68
0.62
%
0.38
25
142
25
142
1.84
2.01
7.6
2.4
1.66
1.16
%
0.75
25
142
177
1966
0.69
1.99
5.8
4.5
1.63
1.29
mmol/l
5.56
168
1792
12
51
2.42
1.98
1.7
1.5
—
—
—
0
0
10
39
2.62
1.96
1.6
1.2
—
—
—
0
0
186
1647
1.45
1.96
14.9
7.8
87.89
81.11
u/l
1.19
178
1544
13
60
2.23
1.81
1.6
1.5
—
—
—
0
0
8
29
2.81
1.80
1.1
1.3
—
—
—
0
0
8
29
2.81
1.80
1.6
2.1
—
—
—
0
0
15
74
2.09
1.79
2.3
2.8
0.00
0.07
g/l
0.49
15
64
12
54
2.28
1.76
2.9
1.7
—
—
—
0
0
5
13
3.90
1.72
1.4
3.5
16.36
138.36
u/ml
—
5
13
5
13
3.90
1.72
11.2
2.2
0.20
0.92
index
—
5
13
64
479
1.44
1.72
2.0
1.8
169091320.33
427.31
pmol/l
0.49
55
392
9
187
0.46
1.69
1.3
1.5
—
—
—
0
0
13
62
2.15
1.68
2.3
3.0
0.00
0.00
g/l
-0.00
13
56
8
31
2.63
1.67
1.6
2.1
—
—
—
0
0
6
19
3.21
1.67
1.2
1.1
—
—
—
0
0
52
377
1.47
1.64
4.5
2.9
0.98
1.05
e6/l
0.10
33
204
5
14
3.62
1.62
1.8
1.6
—
—
—
0
0
9
37
2.48
1.49
1.4
1.4
—
—
—
0
0
5
16
3.16
1.44
1.6
1.2
—
—
—
0
0
185
2007
0.73
1.44
44.2
15.5
71.87
78.36
ml/min/173m2
2.29
173
1883
11
53
2.12
1.40
1.8
1.7
—
—
—
0
0
13
68
1.96
1.36
2.3
2.9
0.00
0.00
g/l
-0.00
13
57
69
852
0.74
1.32
2.7
1.9
1.76
1.36
mmol/l
2.85
59
711
9
43
2.13
1.31
1.8
1.6
—
—
—
0
0
9
45
2.03
1.24
1.1
1.2
—
16.82
—
0
6
130
1136
1.29
1.22
6.0
3.8
0.00
0.00
estimate
-0.00
26
245
17
102
1.71
1.19
2.1
1.4
0.37
0.34
mg/l
—
9
41
212
2236
0.73
1.16
80.4
23.9
122.19
136.55
g/l
20.70
207
2212
5
20
2.53
1.15
11.4
2.3
17.00
14.92
index
—
5
13
212
2235
0.73
1.15
79.9
23.7
4.18
4.52
e12/l
9.92
205
2179
212
2235
0.73
1.15
80.8
24.1
37.11
40.64
%
14.36
207
2209
47
359
1.38
1.13
4.8
3.1
3.02
1.52
e6/l
1.05
28
190
8
40
2.03
1.13
8.4
3.6
20.71
10.20
pmol/l
—
8
40
212
2233
0.73
1.11
79.9
23.8
267.27
240.90
e9/l
4.05
206
2188
212
2233
0.73
1.11
79.6
23.7
90.74
91.43
fl
1.02
207
2209
131
1156
1.27
1.11
3.4
2.7
—
—
—
0
0
77
636
1.30
1.10
5.9
3.9
0.00
0.01
estimate
0.50
19
222
127
1120
1.26
1.07
5.9
3.8
0.00
0.00
estimate
-0.00
25
244
108
935
1.26
1.06
8.5
3.9
56.05
97.54
ng/l
0.33
92
720
172
1574
1.27
1.04
7.2
4.3
26.61
12.59
mm/h
8.27
165
1460
11
60
1.87
1.04
1.5
1.3
—
—
—
0
0
16
101
1.62
0.96
1.3
1.2
117.17
112.69
u/ml
—
6
40
128
1143
1.23
0.93
6.1
3.9
0.00
1.35
estimate
0.51
23
225
6
28
2.17
0.92
1.3
1.5
—
—
—
0
0
177
1892
0.80
0.90
5.7
5.1
1.76
1.96
mu/l
1.54
168
1707
28
205
1.41
0.88
2.7
2.8
0.41
0.64
e6/l
0.21
28
199
6
30
2.02
0.87
1.3
1.4
—
—
—
0
0
99
865
1.23
0.87
6.1
3.9
0.00
0.00
estimate
-0.00
18
204
6
31
1.96
0.85
1.0
1.1
—
17.83
—
0
6
10
58
1.75
0.81
1.7
1.4
—
—
—
0
0
9
53
1.72
0.76
1.8
1.5
—
—
—
0
0
5
24
2.10
0.75
1.0
1.3
1.81
1.52
g/l
—
5
19
9
59
1.54
0.69
1.1
1.2
—
2.82
—
0
11
5
29
1.74
0.64
1.4
1.4
—
—
—
0
0
5
29
1.74
0.64
1.4
1.4
—
—
—
0
0
32
254
1.30
0.63
27.8
7.0
—
—
—
0
0
211
2190
0.81
0.62
63.8
21.0
110.22
81.44
umol/l
3.87
206
2166
5
30
1.68
0.61
1.4
1.4
—
—
—
0
0
5
30
1.68
0.61
1.2
1.1
—
—
—
0
0
5
30
1.68
0.61
1.4
1.4
—
—
—
0
0
0
22
0.00
0.59
0.0
1.0
—
502.00
—
0
12
0
22
0.00
0.59
0.0
1.0
—
39.41
—
0
10
8
55
1.47
0.56
1.1
1.3
—
—
—
0
0
150
1404
1.16
0.55
5.8
3.2
93.26
52.95
u/l
2.08
142
1321
9
61
1.49
0.54
1.3
1.4
—
—
—
0
0
41
344
1.23
0.53
1.3
1.3
2.30
12.98
u/ml
1.62
14
133
191
1991
0.85
0.52
11.8
6.9
50.19
40.18
mmol/mol
11.07
181
1863
50
431
1.20
0.50
1.6
1.3
2.24
1.55
u/ml
—
10
123
5
31
1.62
0.43
1.2
2.7
3.18
122.11
u/ml
—
5
31
0
15
0.00
0.41
0.0
2.2
—
—
—
0
0
0
15
0.00
0.41
0.0
2.2
—
—
—
0
0
0
15
0.00
0.41
0.0
2.1
—
—
—
0
0
0
15
0.00
0.41
0.0
2.2
—
—
—
0
0
0
15
0.00
0.41
0.0
2.2
—
—
—
0
0
8
60
1.34
0.40
1.3
1.1
—
—
—
0
0
8
60
1.34
0.40
1.3
1.1
—
—
—
0
0
8
60
1.34
0.40
1.3
1.7
—
—
—
0
0
211
2055
1.14
0.32
64.9
15.5
33.65
25.14
mg/l
3.50
196
1693
15
186
0.79
0.32
1.3
1.4
—
—
—
0
0
7
54
1.30
0.30
1.4
1.4
—
—
—
0
0
15
123
1.23
0.26
1.7
1.8
—
—
—
0
0
42
381
1.12
0.24
1.3
1.3
53.93
30.59
iu/ml
0.24
14
125
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.2
—
45.33
—
0
12
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
3.8
—
174.54
—
0
13
67
629
1.09
0.20
5.2
3.5
0.00
0.13
estimate
0.50
20
186
0
14
0.00
0.20
0.0
2.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.5
—
13.24
—
0
14
0
14
0.00
0.20
0.0
2.2
—
—
—
0
0
6
53
1.14
0.19
1.0
1.3
—
—
—
0
0
16
139
1.16
0.16
1.6
1.9
—
—
—
0
0
8
72
1.11
0.16
2.3
2.0
177.00
217.70
pmol/l
—
8
67
6
79
0.75
0.15
1.5
1.7
6.23
2.66
mg/l
—
6
58
11
94
1.18
0.13
1.3
1.3
—
—
—
0
0
30
281
1.08
0.10
1.3
1.5
—
—
—
0
0
5
44
1.14
0.10
1.0
1.7
—
—
—
0
0
46
450
1.03
0.03
2.7
2.8
2.45
2.45
mmol/l
0.05
39
408
156
1549
1.02
0.02
4.0
4.1
15.08
14.89
pmol/l
0.38
142
1407
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
5.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
57
0.87
-0.00
1.8
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
0.20
—
0
9
8
87
0.92
-0.00
1.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: ST19_COMPLICATIO_PECUL_REATTACHM_AMPUT – Complications peculiar to reattachment and amputation
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).